# EDGAR Filing Document

**Accession Number:** 0001533615
**File Stem:** 0001104659-26-057206
**Filing Date:** 2026-5
**Character Count:** 256373
**Document Hash:** 7ad5dd6d5966f1abeec242db14a7af41
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-26-057206.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001104659-26-057206

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 65

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Chiron Real Estate Inc.
- **CENTRAL INDEX KEY:** 0001533615
- **STANDARD INDUSTRIAL CLASSIFICATION:** REAL ESTATE INVESTMENT TRUSTS [6798]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 464757266
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37815
- **FILM NUMBER:** 26954203

**BUSINESS ADDRESS:**
- **STREET 1:** 7373 WISCONSIN AVENUE
- **STREET 2:** SUITE 800
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20814
- **BUSINESS PHONE:** 202-524-6851

**MAIL ADDRESS:**
- **STREET 1:** 7373 WISCONSIN AVENUE
- **STREET 2:** SUITE 800
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20814

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Global Medical REIT Inc.
- **DATE OF NAME CHANGE:** 20140207

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** SCOOP MEDIA, INC.
- **DATE OF NAME CHANGE:** 20111027

?xml version='1.0' encoding='ASCII'? Chiron Real Estate Inc._March 31, 2026

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 10-Q**

---

| | |
|:---|:---|
| ☑ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

**For the quarterly period ended March 31, 2026**

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ___________ to ___________**

**Commission file number: 001-37815**

**Chiron Real Estate Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Maryland** | **46-4757266** |
| (State or other jurisdiction of incorporation or<br>organization) | (I.R.S. Employer Identification No.) |
| **7373 Wisconsin Avenue, Suite 800**<br>**Bethesda, MD**  | <br>**20814** |
| (Address of principal executive offices) | (Zip Code) |

---

---

| |
|:---|
| Registrant's telephone number, including area code: **(202) 524-6851** |
| **N/A** |
| (Former name, former address and former fiscal year, if changed since last report) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class:** | **Trading Symbol(s):** | **Name of each exchange on which registered:** |
| Common Stock, par value $0.001 per share | XRN | NYSE |
| Series A Preferred Stock, par value $0.001 per share | XRN PrA | NYSE |
| Series B Preferred Stock, par value $0.001 per share | XRN PrB | NYSE |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 🗹 Yes ◻ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes 🗹 No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer  | ☐ | Accelerated filer | 🗹 |
| Non-accelerated filer  | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

The number of shares of the registrant's common stock outstanding at May 5, 2026 was 13,234,830.

**TABLE OF CONTENTS**

**PART I FINANCIAL INFORMATION**

---

| | | |
|:---|:---|:---|
| Item 1. | Financial Statements (Unaudited) |  |
|  | [Condensed Consolidated Balance Sheets – March 31, 2026 and December 31, 2025](#CondensedConsolidatedBalanceSheets_69813) | 3 |
|  | [Condensed Consolidated Statements of Operations – Three Months Ended March 31, 2026 and 2025](#CondensedConsolidatedStatementsofOperati) | 4 |
|  | [Condensed Consolidated Statements of Comprehensive Income – Three Months Ended March 31, 2026 and 2025](#CondensedConsolidatedStatementsofCompreh) | 5 |
|  | [Condensed Consolidated Statements of Equity – Three Months Ended March 31, 2026 and 2025](#CondensedConsolidatedStatementsofEquity_) | 6 |
|  | [Condensed Consolidated Statements of Cash Flows –Three Months Ended March 31, 2026 and 2025](#CondensedConsolidatedStatementsofCashFlo) | 7 |
|  | [Notes to the Unaudited Condensed Consolidated Financial Statements](#NotestotheUnauditedCondensedConsolidated) | 8 |
| [Item 2.](#Item2ManagementsDiscussionandAnalysisofF) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#Item2ManagementsDiscussionandAnalysisofF) | 24 |
| [Item 3.](#Item3QuantitativeandQualitativeDisclosur) | [Quantitative and Qualitative Disclosures About Market Risk](#Item3QuantitativeandQualitativeDisclosur) | 38 |
| [Item 4.](#Item4ControlsandProcedures_503317) | [Controls and Procedures](#Item4ControlsandProcedures_503317) | 38 |
| [**PART II OTHER INFORMATION**](#PARTIIOTHERINFORMATION_320473) | [**PART II OTHER INFORMATION**](#PARTIIOTHERINFORMATION_320473) | [**PART II OTHER INFORMATION**](#PARTIIOTHERINFORMATION_320473) |
| [Item 1.](#Item1LegalProceedings_452324) | [Legal Proceedings](#Item1LegalProceedings_452324) | 39 |
| [Item 1A.](#Item1ARiskFactors_398303) | [Risk Factors](#Item1ARiskFactors_398303) | 39 |
| [Item 2.](#Item2UnregisteredSalesofEquitySecurities) | [Unregistered Sales of Equity Securities and Use of Proceeds](#Item2UnregisteredSalesofEquitySecurities) | 42 |
| [Item 3.](#Item3DefaultsUponSeniorSecurities_323266) | [Defaults Upon Senior Securities](#Item3DefaultsUponSeniorSecurities_323266) | 42 |
| [Item 4.](#Item4MineSafetyDisclosures_52839) | [Mine Safety Disclosures](#Item4MineSafetyDisclosures_52839) | 42 |
| [Item 5.](#Item5OtherInformation_67200) | [Other Information](#Item5OtherInformation_67200) | 42 |
| [Item 6.](#Item6Exhibits_927483) | [Exhibits](#Item6Exhibits_927483) | 43 |
| [Signatures](#SIGNATURES_97611) | [Signatures](#SIGNATURES_97611) | 45 |

---

#### CHIRON REAL ESTATE INC.
**Condensed Consolidated Balance Sheets**

**(unaudited and in thousands, except par values)**

---

| | | |
|:---|:---|:---|
|  | **As of** | **As of** |
|  | **March 31, 2026** | **December 31, 2025** |
| **Assets** |  |  |
| Investment in real estate: |  |  |
| &nbsp;&nbsp;Land | $169917 | $169917 |
| &nbsp;&nbsp;Building | 1073953 | 1072124 |
| &nbsp;&nbsp;Site improvements | 25783 | 25741 |
| &nbsp;&nbsp;Tenant improvements | 81168 | 80397 |
| &nbsp;&nbsp;Acquired lease intangible assets | 144573 | 144573 |
|  | 1495394 | 1492752 |
| &nbsp;&nbsp;Less: accumulated depreciation and amortization | (353309) | (338096) |
| Investment in real estate, net | 1142085 | 1154656 |
| Cash and cash equivalents | 8183 | 9084 |
| Restricted cash | 2778 | 2805 |
| Tenant receivables, net | 6800 | 7225 |
| Due from related parties | 177 | 162 |
| Escrow deposits | 546 | 556 |
| Deferred assets | 29953 | 28907 |
| Derivative assets | 7218 | 6102 |
| Goodwill | 5903 | 5903 |
| Investment in unconsolidated joint ventures | 8902 | 1781 |
| Other assets | 25474 | 25284 |
| Total assets | $1238019 | $1242465 |
| **Liabilities and Equity** |  |  |
| Liabilities: |  |  |
| Credit Facility, net of unamortized debt issuance costs of $9,686 and $10,476 at March 31, 2026 and December 31, 2025, respectively | $662314 | $652699 |
| Notes payable, net of unamortized debt issuance costs of $0 at March 31, 2026 and December 31, 2025 | 1096 | 1153 |
| Accounts payable and accrued expenses | 15022 | 18289 |
| Dividends payable | 12708 | 12484 |
| Security deposits | 3486 | 3421 |
| Other liabilities | 18368 | 19410 |
| Acquired lease intangible liabilities, net | 4375 | 4944 |
| &nbsp;&nbsp;Total liabilities | 717369 | 712400 |
| Commitments and Contingencies |  |  |
| Equity: |  |  |
| Preferred stock, $0.001 par value, 10,000 shares authorized; 5,155 shares issued and outstanding at March 31, 2026 and December 31, 2025 (liquidation preference of $128,875 at March 31, 2026 and December 31, 2025) | 124106 | 124106 |
| Common stock, $0.001 par value, 100,000 shares authorized; 13,235 shares issued and outstanding at March 31, 2026 and December 31, 2025 | 13 | 13 |
| Additional paid-in capital | 729514 | 729514 |
| Accumulated deficit | (360640) | (349965) |
| Accumulated other comprehensive income | 7218 | 6102 |
| &nbsp;&nbsp;Total Chiron Real Estate Inc. stockholders' equity | 500211 | 509770 |
| Noncontrolling interest | 20439 | 20295 |
| &nbsp;&nbsp;Total equity | 520650 | 530065 |
| Total liabilities and equity | $1238019 | $1242465 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Condensed Consolidated Statements of Operations**

**(unaudited and in thousands, except per share amounts)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| **Revenue** |  |  |
| Rental revenue | $38021 | $34595 |
| Other income | 43 | 23 |
| &nbsp;&nbsp;Total revenue | 38064 | 34618 |
| **Expenses** |  |  |
| General and administrative | 5089 | 3620 |
| Operating expenses | 9250 | 7585 |
| Depreciation expense | 11087 | 10307 |
| Amortization expense | 3740 | 3520 |
| Interest expense | 7233 | 7167 |
| &nbsp;&nbsp;Total expenses | 36399 | 32199 |
| &nbsp;&nbsp;Income before other income (expense) | 1665 | 2419 |
| &nbsp;&nbsp;Gain on sale of investment properties |  | 1358 |
| &nbsp;&nbsp;Equity loss from unconsolidated joint ventures | (11) | (40) |
| &nbsp;&nbsp;Net income  | $1654 | $3737 |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Preferred stock dividends | (2473) | (1455) |
| &nbsp;&nbsp;&nbsp;&nbsp;Less: Net loss (income) attributable to noncontrolling interest | 70 | (178) |
| &nbsp;&nbsp;**Net (loss) income attributable to common stockholders**  | $**(749)** | $**2104** |
| Net (loss) income attributable to common stockholders per share – basic and diluted | $(0.06) | $0.16 |
| Weighted average shares outstanding – basic and diluted | 13235 | 13374 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Condensed Consolidated Statements of Comprehensive Income** 

**(unaudited and in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| Net income  | $1654 | $3737 |
| Other comprehensive income (loss): |  |  |
| &nbsp;&nbsp; Increase (decrease) in fair value of interest rate swap agreements | 1116 | (4900) |
| &nbsp;&nbsp; Total other comprehensive income (loss) | 1116 | (4900) |
| Comprehensive income (loss) | 2770 | (1163) |
| Less: Preferred stock dividends | (2473) | (1455) |
| Less: Comprehensive (income) loss attributable to noncontrolling interest | (26) | 205 |
| Comprehensive income (loss) attributable to common stockholders | $271 | $(2413) |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Condensed Consolidated Statements of Equity**

**(unaudited and in thousands, except per share amounts)**

**For the Three Months Ended March 31, 2026:**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | | | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | <br>**Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br>**Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income**  | **Chiron**<br>**Real**<br>**Estate Inc.**<br>**Stockholders'**<br>**Equity** | <br>**Non-**<br>**controlling**<br>**Interest** | <br>**Total**<br>**Equity** |
| Balances, December 31, 2025 | 13235 | $13 | 5155 | $124106 | $729514 | $(349965) | $6102 | $509770 | $20295 | $530065 |
| Net income (loss) |  |  |  |  |  | 1724 |  | 1724 | (70) | 1654 |
| Change in fair value of interest rate swap agreements |  |  |  |  |  |  | 1116 | 1116 |  | 1116 |
| Stock-based compensation expense |  |  |  |  |  |  |  |  | 1229 | 1229 |
| Dividends to common stockholders |  |  |  |  |  | (9926) |  | (9926) |  | (9926) |
| Dividends to preferred stockholders |  |  |  |  |  | (2473) |  | (2473) |  | (2473) |
| Dividends to noncontrolling interest |  |  |  |  |  |  |  |  | (1015) | (1015) |
| Balances, March 31, 2026 | 13235 | $13 | 5155 | $124106 | $729514 | $(360640) | $7218 | $500211 | $20439 | $520650 |

---

**For the Three Months Ended March 31, 2025:**

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | **Preferred Stock** | **Preferred Stock** | | | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | <br>**Additional**<br>**Paid-in**<br>**Capital** | <br>**Accumulated**<br>**Deficit** | <br>**Accumulated**<br>**Other**<br>**Comprehensive**<br>**Income**  | **Chiron**<br>**Real**<br>**Estate Inc.**<br>**Stockholders'**<br>**Equity** | <br>**Non-**<br>**controlling**<br>**Interest** | <br>**Total**<br>**Equity** |
| Balances, December 31, 2024 | 13374 | $13 | 3105 | $74959 | $734277 | $(293736) | $18613 | $534126 | $21790 | $555916 |
| Net income |  |  |  |  |  | 3559 |  | 3559 | 178 | 3737 |
| LTIP Units redeemed for common stock | 2 |  |  |  | 67 |  |  | 67 | (67) |  |
| Change in fair value of interest rate swap agreements |  |  |  |  |  |  | (4900) | (4900) |  | (4900) |
| Stock-based compensation expense |  |  |  |  |  |  |  |  | 151 | 151 |
| Dividends to common stockholders |  |  |  |  |  | (14045) |  | (14045) |  | (14045) |
| Dividends to preferred stockholders |  |  |  |  |  | (1455) |  | (1455) |  | (1455) |
| Dividends to noncontrolling interest |  |  |  |  |  |  |  |  | (1301) | (1301) |
| Balances, March 31, 2025 | 13376 | $13 | 3105 | $74959 | $734344 | $(305677) | $13713 | $517352 | $20751 | $538103 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Condensed Consolidated Statements of Cash Flows**

**(unaudited and in thousands)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| **Operating activities** |  |  |
| Net income  | $1654 | $3737 |
| &nbsp;&nbsp;Adjustments to reconcile net income (loss) to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation expense | 11087 | 10307 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of acquired lease intangible assets | 3412 | 3287 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of above market leases, net | 146 | 452 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs and other | 807 | 559 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | 1229 | 151 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gain on sale of investment properties |  | (1358) |
| &nbsp;&nbsp;&nbsp;&nbsp;Equity loss from unconsolidated joint venture | 11 | 40 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other  | (53) | 25 |
| &nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Tenant receivables | 425 | (680) |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred assets | (1046) | (57) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (1597) | (2987) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (2788) | (1254) |
| &nbsp;&nbsp;&nbsp;&nbsp;Security deposits  | 65 | 50 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 13352 | 12272 |
| **Investing activities** |  |  |
| Purchase of land, buildings, and other tangible and intangible assets and liabilities |  | (31978) |
| Net proceeds from sale of investment properties |  | 7783 |
| Investment in unconsolidated joint venture | (7165) |  |
| Distribution of capital from unconsolidated joint venture | 33 | 33 |
| Escrow deposits for purchase of properties |  | (186) |
| Advances made to related parties | (15) | (150) |
| Capital expenditures on existing real estate investments | (2145) | (2611) |
| Leasing commissions | (550) | (115) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities | (9842) | (27224) |
| **Financing activities** |  |  |
| Escrow deposits required by third party lenders |  | (18) |
| Repayment of notes payable  | (57) | (160) |
| Proceeds from Credit Facility | 17100 | 44000 |
| Repayment of Credit Facility | (8275) | (13500) |
| Payment of debt issuance costs | (17) |  |
| Dividends paid to common stockholders, and OP Unit and LTIP Unit holders | (10939) | (15269) |
| Dividends paid to preferred stockholders | (2251) | (1455) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) provided by financing activities | (4439) | 13598 |
| Net decrease in cash and cash equivalents and restricted cash | (929) | (1354) |
| Cash and cash equivalents and restricted cash—beginning of period | 11890 | 8942 |
| Cash and cash equivalents and restricted cash—end of period | $10961 | $7588 |
| **Supplemental cash flow information:** |  |  |
| Cash payments for interest | $6533 | $6568 |
| **Noncash financing and investing activities:** |  |  |
| Accrued dividends payable | $12708 | $16597 |
| Interest rate swap agreements fair value change recognized in other comprehensive income (loss) | $(1116) | $4900 |
| LTIP Units and OP Units redeemed for common stock | $— | $67 |
| Accrued capital expenditures and leasing commissions included in accounts payable and accrued expenses | $889 | $1769 |
| Recognition of lease liability related to right of use asset | $— | $3851 |

---

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

**Notes to the Unaudited Condensed Consolidated Financial Statements**

**(dollars in thousands, except per share amounts or as otherwise indicated)**

#### Note 1 – Organization
Chiron Real Estate Inc. (the "Company") is a Maryland corporation and internally managed real estate investment trust ("REIT") that primarily acquires (i) healthcare facilities leased to physician groups and regional and national healthcare systems and (ii) seniors housing communities. The Company holds its facilities and conducts its operations through a Delaware limited partnership subsidiary, Chiron Real Estate LP (the "Operating Partnership"). The Company serves as the sole general partner of the Operating Partnership through a wholly owned subsidiary of the Company, Chiron Real Estate GP LLC, a Delaware limited liability company. As of March 31, 2026, the Company owned 91.4% of the outstanding common operating partnership units ("OP Units"), with the remaining 8.6% owned by holders of long-term incentive plan units ("LTIP Units") and third-party limited partners who contributed properties or services in exchange for OP Units.

#### Note 2 – Summary of Significant Accounting Policies

#### Basis of presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Certain information and footnote disclosures required for annual consolidated financial statements have been condensed or excluded pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements and notes thereto for the year ended December 31, 2025. In the opinion of management, all adjustments, consisting of normal and recurring adjustments, considered necessary for a fair presentation of the interim financial statements presented have been included.

#### Principles of Consolidation
The accompanying condensed consolidated financial statements include the accounts of the Company, including the Operating Partnership, its wholly owned subsidiaries, and its equity investment in unconsolidated joint ventures. The Company presents the portion of any equity it does not own but controls (and thus consolidates) as noncontrolling interest. Noncontrolling interest in the Company includes the LTIP Units that have been granted to directors, officers and affiliates of the Company and the OP Units held by third parties. Refer to Note 5 – "Equity" and Note 7 – "Stock-Based Compensation" for additional information regarding the OP Units and LTIP Units.

The Company classifies noncontrolling interest as a component of consolidated equity on its Condensed Consolidated Balance Sheets, separate from the Company's total equity. The Company's net income or loss is allocated to noncontrolling interests based on the respective ownership or voting percentage in the Operating Partnership associated with such noncontrolling interests and is removed from consolidated income or loss on the Condensed Consolidated Statements of Operations in order to derive net income or loss attributable to common stockholders. The noncontrolling ownership percentage is calculated by dividing the aggregate number of LTIP Units and OP Units by the total number of units and shares outstanding.

#### Use of Estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and footnotes. Actual results could differ from those estimates.

#### Cash and Cash Equivalents and Restricted Cash
The Company considers all demand deposits, cashier's checks, money market accounts, and certificates of deposit with a maturity of three months or less to be cash equivalents. Amounts included in restricted cash represent certain security deposits received from tenants at the inception of their leases and funds held by the Company related to certain tenant reimbursements. The following table provides a reconciliation of the Company's cash and cash equivalents and restricted cash:

---

| | | |
|:---|:---|:---|
|  | **As of March 31,**  | **As of March 31,**  |
|  | **2026** | **2025** |
| Cash and cash equivalents | $8183 | $5412 |
| Restricted cash | 2778 | 2176 |
| &nbsp;&nbsp;Total cash and cash equivalents and restricted cash | $10961 | $7588 |

---

#### Tenant Receivables, Net
Tenant receivables consist primarily of amounts due from tenants for contractual rent and tenant reimbursements for real estate taxes, insurance, and certain other operating expenses. Receivables arising from operating leases are accounted for in accordance with ASC Topic 842 "Leases" ("ASC Topic 842"). The Company evaluates the collectability of tenant receivables at each reporting date by monitoring the creditworthiness and liquidity of its tenants and assessing historical collection experience and current economic conditions. If the collection of substantially all lease payments is no longer considered probable, the Company ceases recognizing revenue on a straight-line basis and recognizes revenue only as cash is received. As of March 31, 2026 and December 31, 2025, the Company had a portfolio level reserve of $350 related to tenant receivables considered probable of collection.

#### Deferred Assets
The deferred assets balance as of March 31, 2026 and December 31, 2025 was $29,953 and $28,907, respectively. The balance for both periods consisted primarily of deferred rent receivables resulting from the recognition of rental revenue on a straight-line basis over the terms of tenant leases with contractual lease payments in accordance with ASC 842 Leases.

**Derivative Assets - Interest Rate Swaps**

The derivative assets balance as of March 31, 2026 and December 31, 2025, was $7,218 and $6,102, respectively. In accordance with the Company's risk management strategy, the purpose of the interest rate swaps is to manage interest rate risk for certain of the Company's variable-rate debt. The interest rate swaps involve the Company's receipt of variable-rate amounts from the counterparties in exchange for the Company making fixed-rate payments over the life of the agreements. The Company accounts for derivative instruments in accordance with the provisions of ASC Topic 815, "Derivatives and Hedging." Refer to Note 4 – "Credit Facility, Notes Payable and Derivative Instruments" for additional details.

**Goodwill**

The Company's goodwill balance was $5,903 as of March 31, 2026 and December 31, 2025. Goodwill represents the excess of consideration paid over the fair value of underlying identifiable net assets of businesses acquired. Goodwill has an indefinite life and is not amortized. The Company tests goodwill for impairment on an annual basis, or more frequently if events or changes in circumstances indicate potential impairment. The Company has one reporting unit.

**Unconsolidated Joint Ventures**

*GII Joint Venture*

In December 2024, the Company sold certain assets to a newly formed joint venture, GII Global Medical Holdings LLC (the "GII Joint Venture"), with the Company, through its Operating Partnership, and Heitman Global Real Estate REIT LLC ("Heitman") and their subsidiaries. The Company retained a 12.5% ownership interest, and Heitman retains the remaining 87.5%. Heitman, through its voting interest, controls the GII Joint Venture. The Heitman Joint Venture obtained a mortgage loan with a principal balance of $17.6 million.

*Active Adult Joint Venture*

On January 6, 2026, the Company entered into a joint venture with a developer to facilitate the development of an active adult residential community near Minneapolis, Minnesota (the "Active Adult Joint Venture"). The Company invested $7.1 million for a 49%

equity interest, with the developer retaining a 51% interest and serving as the managing member. The Active Adult Joint Venture obtained a construction loan with a principal balance of $31.0 million.

The Company accounts for its joint venture investments using the equity method. Under this method, the investment is initially recorded at cost and subsequently adjusted for the Company's share of net income or loss, as well as any cash contributions or distributions. The net equity investment is included in the "Investment in unconsolidated joint venture" line on the Condensed Consolidated Balance Sheets, and the Company's share of net income or loss is included in "Equity income (loss) from unconsolidated joint venture" on the Condensed Consolidated Statements of Operations. Distributions are classified as operating cash inflows to the extent of cumulative equity in earnings recognized, with any excess classified as investing cash inflows.

**Other Assets**

Other assets consisted of the following as of March 31, 2026 and December 31, 2025. Refer to Note 8 – "Leases" for additional details on right of use assets.

---

| | | |
|:---|:---|:---|
|  | **As of March 31,** <br>**2026** | **As of December 31,**<br>**2025** |
| Right of use assets | $12981 | $13102 |
| Capitalized construction in process costs | 1757 | 2551 |
| Prepaid assets | 2530 | 1539 |
| Capitalized leasing commissions, net | 7923 | 7784 |
| Capitalized software costs and miscellaneous assets, net | 283 | 308 |
| &nbsp;&nbsp;Total Other assets | $25474 | $25284 |

---

**Other Liabilities**

The other liabilities balance as of March 31, 2026 and December 31, 2025 was $18,368 and $19,410, respectively. The balance as of March 31, 2026 consisted of $13,338 for right of use liabilities and $5,030 of prepaid rent. The balance as of December 31, 2025 consisted of $13,438 for right of use liabilities and $5,972 of prepaid rent. Refer to Note 8 – "Leases" for additional details on right of use liabilities.

**Segment Reporting** 

In December 2024, the Company adopted ASU No. 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures," for its fiscal year 2024 annual financial statements and interim financial statements thereafter. The adoption of ASU 2023-07 did not have a material impact on the Company's financial condition, results of operations, or disclosures.

The Company acquires healthcare facilities leased to physician groups and regional and national healthcare systems. The Company operates and manages its business as one reportable operating segment. Resources are allocated and financial performance is assessed by the Company's Chief Executive Officer, its chief operating decision maker, or the CODM. The CODM reviews total consolidated assets and consolidated net income or loss and uses this information to assess the performance of the Company's portfolio and makes operating decisions accordingly. There are no significant segment operating expenses that require disclosure other than the expense categories on the Company's Consolidated Statements of Operations.

**New Accounting Pronouncements**

In November 2024, the FASB issued ASU No. 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), to address requests from investors for more detailed information about the types of expenses in commonly presented expense captions. ASU 2024-03 requires public companies to provide disaggregated disclosure in tabular format in the notes to financial statements of specific expenses, including but not limited to: (i) employee compensation, (ii) depreciation, and (iii) intangible asset amortization. In January 2025, the FASB issued ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, which clarifies that the amendments in ASU 2024-03 are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. The Company is evaluating the impact ASU 2024-03 will have on its disclosures.

In December 2025, the FASB issued ASU No. 2025-11, Interim Reporting (Topic 270): Narrow-Scope Improvements ("ASU 2025-11"), to improve the guidance in ASC Topic 270, Interim Reporting, including by clarifying when Topic 270 is applicable, improving the navigability of interim disclosure requirements, and establishing a principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. For public business entities, ASU 2025-11 is effective

for interim reporting periods within annual reporting periods beginning after December 15, 2027 (and for entities other than public business entities, beginning after December 15, 2028). Early adoption is permitted, and the amendments may be applied retrospectively or prospectively. The Company is evaluating the impact ASU 2025-11 will have on its disclosures.

#### Note 3 – Property Portfolio

#### Summary of Properties Acquired and Sold During the Three Months Ended March 31, 2026
During the three months ended March 31, 2026, the Company completed no acquisitions or dispositions.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of March 31, 2026 is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Land** | <br>**Building** | **Site**<br>**Improvements** | **Tenant**<br>**Improvements** | **Acquired Lease**<br>**Intangible Assets** | **Gross Investment in**<br>**Real Estate** |
| Balances as of December 31, 2025 | $169917 | $1072124 | $25741 | $80397 | $144573 | $1492752 |
| Capitalized costs<sup>(1)</sup> |  | 1829 | 42 | 771 |  | 2642 |
| Total Additions: |  | 1829 | 42 | 771 |  | 2642 |
| Balances as of March 31, 2026 | $169917 | $1073953 | $25783 | $81168 | $144573 | $1495394 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Represents capital projects that were completed and placed in service during the three months ended March 31, 2026 related to the Company's existing facilities.

Depreciation expense was $11,087 and $10,307 for the three months ended March 31, 2026 and 2025, respectively.

As of March 31, 2026, the Company had aggregate capital improvement commitments and obligations to improve, expand, and maintain the Company's existing facilities of approximately $29,000. Many of these amounts are subject to contingencies that make it difficult to predict when they will be utilized, if at all. In accordance with the terms of the Company's leases, capital improvement obligations in the next twelve months are expected to total approximately $14,900.

#### Summary of Properties Acquired and Sold During the Year Ended December 31, 2025
During the year ended December 31, 2025, the Company completed the acquisition of a five-property portfolio of medical real estate. For this acquisition, substantially all of the fair value was concentrated in a single identifiable asset or group of similar identifiable assets and, therefore, this acquisition represented an asset acquisition. Accordingly, $1.0 million of transaction costs for this acquisition were capitalized.

During the year ended December 31, 2025, the Company completed seven dispositions for approximately $23.0 million, realizing an aggregate net gain of approximately $1.5 million. In addition, we recognized impairment losses on the sold assets of $13.0 million.

A rollforward of the gross investment in land, building, improvements, and acquired lease intangible assets as of December 31, 2025 is as follows:

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | <br>**Land** | <br>**Building** | **Site**<br>**Improvements** | **Tenant**<br>**Improvements** | **Acquired Lease**<br>**Intangible Assets** | **Gross Investment in**<br>**Real Estate** |
| Balances as of December 31, 2024 | $174300 | $1044019 | $23973 | $69679 | $138945 | $1450916 |
| Facility Acquired – Date Acquired: |  |  |  |  |  |  |
| Carondelet - 2/7/25 |  | 13327 |  | 1274 | 1725 | 16326 |
| Silverbell - 2/7/25 |  | 8482 |  | 973 | 1368 | 10823 |
| Slippery Rock - 2/7/25 |  | 3511 | 455 | 593 | 572 | 5131 |
| Clive - 4/1/25 |  | 11400 | 507 | 1595 | 2218 | 15720 |
| Des Moines - 4/1/25 |  | 18917 | 182 | 3289 | 3519 | 25907 |
| Capitalized costs<sup>(1)</sup> |  | 5927 | 1226 | 5008 |  | 12161 |
| Total Additions: |  | 61564 | 2370 | 12732 | 9402 | 86068 |
| Facility Sold – Date Sold: |  |  |  |  |  |  |
| Derby - 2/18/25 | (146) | (1250) | (118) | (73) | (372) | (1959) |
| Coos Bay - 3/19/25 | (861) | (5096) | (56) | (49) | (410) | (6472) |
| Chipley - 4/30/25 | (170) | (875) | (34) | (111) | (189) | (1379) |
| 2999 Germantown - 8/7/25 | (253) | (1593) |  |  |  | (1846) |
| Aurora - 9/4/25 | (339) | (2345) | (308) | (603) | (2680) | (6275) |
| Memphis Exeter - 11/4/25 | (232) | (1912) |  |  |  | (2144) |
| Melbourne - 12/30/25 | (1200) | (8556) | (86) | (1178) | (123) | (11143) |
| Total Dispositions: | (3201) | (21627) | (602) | (2014) | (3774) | (31218) |
| Impairment of investment properties<sup>(2)</sup> | (1182) | (11832) |  |  |  | (13014) |
| Balances as of December 31, 2025 | $169917 | $1072124 | $25741 | $80397 | $144573 | $1492752 |

---

<sup>(1)</sup> Represents capital projects that were completed and placed in service during the year ended December 31, 2025 related to the Company's existing facilities.

<sup>(2)</sup> In August 2025, the Company entered into an agreement to sell its facility located in Aurora, Illinois, and recognized an impairment loss of $6.3 million to reduce the carrying value of the asset to its estimated fair value. The fair value was determined based on the contractual sales price, less commissions and fees, and the sale was completed in September 2025. In December 2025, the Company entered into an agreement to sell its facility located in Melbourne, Florida, and recognized an impairment loss of $6.7 million to reduce the carrying value of the asset to its estimated fair value. The fair value was determined based on the contractual sales price, less commissions and fees, and the sale was completed in December 2025.

#### Lease Intangible Assets and Liabilities
The following is a summary of the carrying amount of lease intangible assets and liabilities as of the dates presented:

---

| | | | |
|:---|:---|:---|:---|
|  | **As of March 31, 2026** | **As of March 31, 2026** | **As of March 31, 2026** |
|  | <br>**Cost** | **Accumulated**<br>**Amortization** | <br>**Net** |
| **Assets** |  |  |  |
| In-place leases | $82590 | $(60616) | $21974 |
| Above market leases | 24024 | (15973) | 8051 |
| Leasing costs | 37959 | (26107) | 11852 |
|  | $144573 | $(102696) | $41877 |
| **Liability** |  |  |  |
| Below market leases | $17335 | $(12960) | $4375 |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **As of December 31, 2025** | **As of December 31, 2025** | **As of December 31, 2025** |
|  | <br>**Cost** | **Accumulated**<br>**Amortization** | <br>**Net** |
| **Assets** |  |  |  |
| In-place leases | $82590 | $(58294) | $24296 |
| Above market leases | 24024 | (15258) | 8766 |
| Leasing costs | 37959 | (25017) | 12942 |
|  | $144573 | $(98569) | $46004 |
| **Liability** |  |  |  |
| Below market leases | $17335 | $(12391) | $4944 |

---

The following is a summary of the acquired lease intangible amortization:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended**  | **Three Months Ended**  |
|  | **March 31,**  | **March 31,**  |
|  | **2026** | **2025** |
| Amortization expense related to in-place leases | $2322 | $2215 |
| Amortization expense related to leasing costs | $1090 | $1072 |
| Decrease in rental revenue related to above market leases | $715 | $755 |
| Increase in rental revenue related to below market leases | $(569) | $(303) |

---

As of March 31, 2026, scheduled future aggregate net amortization of the acquired lease intangible assets and liabilities for each year ended December 31 is listed below:

---

| | | |
|:---|:---|:---|
|  | **Net Decrease**<br>**in Revenue** | **Net Increase**<br>**in Expense** |
| 2026 (nine months remaining) | $(330) | $9419 |
| 2027 | (471) | 9408 |
| 2028 | (779) | 6695 |
| 2029 | (831) | 4197 |
| 2030 | (649) | 1785 |
| Thereafter | (615) | 2323 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $(3675) | $33827 |

---

As of March 31, 2026, the weighted average amortization periods for asset lease intangibles and liability lease intangibles were 2.6 years and 2.0 years, respectively.

**Note 4 – Credit Facility, Notes Payable and Derivative Instruments**

#### Credit Facility
On October 8, 2025, the Operating Partnership, as borrower, and certain of its subsidiaries entered into an amended and restated $900 million unsecured syndicated credit facility with JPMorgan Chase Bank, N.A. as administrative agent (the "Credit Facility"). The Credit Facility consists of (i) $500 million of term loans, which include (a) a $350 million loan that is comprised of three term loans as follows: a $100 million term loan maturing in October 2029 ("Term Loan A-1"); a $100 million term loan maturing in October 2030 ("Term Loan A-2"); and a $150 million term loan maturing in April 2031 ("Term Loan A-3," collectively the "Term Loan A Tranches"); and (b) a $150 million term loan maturing in February 2028 ("Term Loan B"), and (ii) a $400 million revolver maturing in October 2029 with two, six-month extension options available at the Company's election (the "Revolver"). The Credit Facility also includes a $500 million accordion feature. Interest rates on amounts outstanding under the Credit Facility equal the term SOFR plus a borrowing spread based on the current pricing grid in the Credit Facility.

The Operating Partnership is subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, and (vii) a minimum net worth of $595.6 million plus 75% of all net proceeds raised through equity offerings subsequent to June 30, 2025. As of March 31, 2026, management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility.

The Company has entered into interest rate swaps to hedge its interest rate risk on the Term Loan A Tranches and Term Loan B through their respective maturities. For additional information related to the interest rate swaps, see the "Derivative Instruments - Interest Rate Swaps" section herein.

During the three months ended March 31, 2026, the Company borrowed $17,100 under the Credit Facility and repaid $8,275, for a net amount borrowed of $8,825. During the three months ended March 31, 2025, the Company borrowed $44,000 under the Credit Facility and repaid $13,500, for a net amount borrowed of $30,500. Interest expense incurred on the Credit Facility was $6,342, and $6,462 for the three months ended March 31, 2026 and 2025, respectively.

As of March 31, 2026 and December 31, 2025, the Company had the following outstanding borrowings under the Credit Facility:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| Revolver | $172000 | $163175 |
| Term Loan A Tranches | 350000 | 350000 |
| Term Loan B | 150000 | 150000 |
| Credit Facility, gross | 672000 | 663175 |
| Less: Unamortized debt issuance costs | (9686) | (10476) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Credit Facility, net | $662314 | $652699 |

---

Costs incurred related to the Credit Facility, net of accumulated amortization, are netted against the Company's "Credit Facility, net of unamortized debt issuance costs" balance in the accompanying Condensed Consolidated Balance Sheets. Amortization expense incurred related to debt issuance costs was $807 and $550 for the three months ended March 31, 2026 and 2025, respectively, and is included in the "Interest Expense" line item in the accompanying Condensed Consolidated Statements of Operations.

#### Notes Payable, Net of Debt Issuance Costs
The Company, through certain of its wholly owned subsidiaries, entered into or assumed a loan in connection with the acquisitions of the Toledo facility. As of March 31, 2026 and December 31, 2025, the Company had the following outstanding borrowings under the loan:

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **December 31, 2025** |
| Toledo loan <sup>(1)</sup> | $1096 | $1153 |
| Unamortized debt issuance costs |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notes payable, net | $1096 | $1153 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) The Toledo loan has an annual interest rate of 5.0% and matures on July 30, 2033.

Amortization expense incurred related to debt issuance costs was $0 and $9 for the three months ended March 31, 2026 and 2025, respectively, and is included in the "Interest Expense" line item in the accompanying Condensed Consolidated Statements of Operations.

The Company made principal payments of $57 and $160 during the three months ended March 31, 2026 and 2025, respectively. Interest expense incurred on notes payable was $18 and $146 for the three months ended March 31, 2026 and 2025, respectively.

As of March 31, 2026, scheduled principal payments due for each year ended December 31 were as follows:

---

| | |
|:---|:---|
| 2026 (nine months remaining) | $59 |
| 2027 | 124 |
| 2028 | 131 |
| 2029 | 139 |
| 2030 | 146 |
| Thereafter | 497 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $1096 |

---

**Senior Note Facility**

On March 2, 2026, the Company entered into a Master Note and Guaranty Agreement (the "Senior Note Agreement") with NYL Investors LLC and certain of its affiliates (collectively, the "Purchasers"). The Senior Note Agreement establishes an uncommitted senior unsecured note facility pursuant to which the Company may issue senior unsecured promissory notes ("Notes") from time to time in one or more series to the Purchasers in an aggregate principal amount of up to $150 million. The Senior Note Agreement does not obligate the Purchasers to purchase any Notes, and each issuance is subject to the Purchasers' discretion and satisfaction of customary conditions. Notes may be issued under the Senior Note Agreement during a period ending on the earliest of (i) the third anniversary of the effective date of the Senior Note Agreement, (ii) termination of the facility by either party upon written notice, (iii) termination following certain events of default, or (iv) acceleration of the Notes and termination of the facility. Notes issued under the Senior Note Agreement may have maturities of up to ten years and will bear interest at rates determined at the time of issuance based on spreads over U.S. Treasury securities. As of March 31, 2026, no Notes had been issued or were outstanding under the Senior Note Agreement.

**Derivative Instruments - Interest Rate Swaps**

As of March 31, 2026, the Company had nine interest rate swaps that are used to manage its interest rate risk by fixing the SOFR component of its term loans through their maturities. Five of the Company's interest rate swaps related to a term loan that was in place prior to the entry into the third amended and restated Credit Facility on October 8, 2025, with a combined notional value of $350 million. These five interest rate swaps remained in place and fixed the SOFR component on that term loan through April 2026 at 1.36%. That term loan was replaced by the Term Loan A Tranches under the third amended and restated Credit Facility. Four of the Company's interest rate swaps related to Term Loan B with a combined notional value of $150 million that fix the SOFR component on Term Loan B through January 2028 at 2.54%. In addition, the Company has seven forward starting interest rate swaps with a combined notional value of $350 million that became effective upon the April 2026 maturity of the existing five interest rate swaps discussed above. These forward starting interest rate swaps fix the SOFR component of the Term Loan A Tranches at rates between 3.24% to 3.32% and have maturities in October 2029, October 2030, and April 2031.

The Company records the swaps either as an asset or a liability measured at its fair value at each reporting period. When hedge accounting is applied, the change in the fair value of derivatives designated and that qualify as cash flow hedges is (i) recorded in accumulated other comprehensive income in the equity section of the Company's Condensed Consolidated Balance Sheets and (ii) subsequently reclassified into earnings as interest expense for the period that the hedged forecasted transactions affect earnings. If specific hedge accounting criteria are not met, changes in the Company's derivative instruments' fair value are recognized currently as an adjustment to net income. As of March 31, 2026 and December 31, 2025, all of the Company's swaps met the criteria for hedge accounting.

The Company's interest rate swaps are not traded on an exchange. The Company's interest rate swaps are recorded at fair value based on a variety of observable inputs including contractual terms, interest rate curves, yield curves, measure of volatility, and correlations of such inputs. The Company measures its derivatives at fair value on a recurring basis based on the expected size of future cash flows on a discounted basis and incorporates a measure of non-performance risk. The fair values are based on Level 2 inputs within the framework of ASC Topic 820. The Company considers its own credit risk, as well as the credit risk of its counterparties, when evaluating the fair value of its derivative instruments.

The fair value of the Company's interest rate swaps was an asset of $7,218 and $6,102 as of March 31, 2026 and December 31, 2025, respectively. The balances are included in the "Derivative Asset" line item on the Company's Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, respectively.

The table below details the components of the amounts presented on the accompanying Condensed Consolidated Statements of Comprehensive Income recognized on the Company's interest rate swaps designated as cash flow hedges for the three months ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| Amount of (gain) loss recognized in other comprehensive income (loss) | $(3576) | $1635 |
| Amount of gain reclassified from accumulated other comprehensive income into interest expense | 2460 | 3265 |
| Total change in accumulated other comprehensive (loss) income | $(1116) | $4900 |

---

During the next twelve months, the Company estimates that an additional $3,426 will be reclassified as a decrease to interest expense. Additionally, during the three months ended March 31, 2026, the Company recorded total interest expense in its Condensed Consolidated Statements of Operations of $7,233.

#### Weighted-Average Interest Rate and Term
The weighted average interest rate and term of the Company's debt was 3.58% and 3.9 years, respectively, at March 31, 2026, compared to 3.74% and 4.1 years as of December 31, 2025.

#### Note 5 – Equity
In September 2025, the Company completed a one-for-five reverse stock split of its outstanding shares of common stock, with a corresponding adjustment to the outstanding partnership units of the Operating Partnership (the "Reverse Stock Split"). Unless otherwise noted, all common share and unit amounts shown herein are shown on a split-adjusted basis.

#### Preferred Stock
The Company's charter authorizes the issuance of 10,000,000 shares of preferred stock, par value $0.001 per share. As of March 31, 2026 and December 31, 2025, there were 3,105,000 shares of Series A Cumulative Redeemable Preferred Stock ("Series A Preferred Stock"), issued and outstanding, and 2,050,000 shares of Series B Cumulative Redeemable Preferred Stock ("Series B Preferred Stock"), issued and outstanding. Each of the Series A Preferred Stock and Series B Preferred Stock has a liquidation preference of $25 per share.

Series A Preferred stock dividend activity for the three months ended March 31, 2026 is summarized in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  | **Quarterly** |  | **Dividends** |
| **Date Announced** | **Record Date** | **Payment Date** | **Dividend** |  | **per Share** |
| December 4, 2025 | January 15, 2026 | February 2, 2026 | $1455 |  | $0.46875 |
| February 25, 2026 | April 15, 2026 | April 30, 2026 | $1455 | (1) | $0.46875 |

---

<sup>(1)</sup> Two months of this amount, equal to $970, was accrued at March 31, 2026.

The holders of the Series A Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Board of Directors (the "Board") (or a duly authorized committee of the Board). The Series A Preferred Stock dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 7.50% of the liquidation preference of $25.00 per share (equivalent to $1.875 per share on an annual basis). Dividends on the Series A Preferred Stock are cumulative and accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The Series A Preferred Stock may be partially or fully redeemed by the Company. The quarterly dividend payment dates on the Series A Preferred Stock are January 31, April 30, July 31 and October 31 of each year. During each of the three-month periods ended March 31, 2026 and 2025, the Company paid preferred dividends of $1,455.

Series B Preferred stock dividend activity for the three months ended March 31, 2026 is summarized in the following table:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  | **Quarterly** |  | **Dividends** |
| **Date Announced** | **Record Date** | **Payment Date** | **Dividend** |  | **per Share** |
| December 4, 2025 | January 15, 2026 | February 2, 2026 | $795 |  | $0.388 |
| February 25, 2026 | April 15, 2026 | April 30, 2026 | $1025 | (1) | $0.500 |

---

<sup>(1)</sup> Two months of this amount, equal to $679, was accrued at March 31, 2026.

The holders of the Series B Preferred Stock are entitled to receive dividend payments only when, as and if declared by the Board (or a duly authorized committee of the Board). The Series B Preferred Stock dividends will accrue or be payable in cash from the original issue date, on a cumulative basis, quarterly in arrears on each dividend payment date at a fixed rate per annum equal to 8.00% of the liquidation preference of $25.00 per share (equivalent to $2.00 per share on an annual basis). Dividends on the Series B Preferred Stock are cumulative and accrue whether or not (i) funds are legally available for the payment of those dividends, (ii) the Company has earnings or (iii) those dividends are declared by the Board. The Series B Preferred Stock may be partially or fully redeemed by the Company beginning in November 2030. The quarterly dividend payment dates on the Series B Preferred Stock are January 31, April 30, July 31 and October 31 of each year. During the three-month period ended March 31, 2026 the Company paid preferred dividends of $795.

#### Common Stock
The Company had 100,000,000 authorized shares of common stock, $0.001 par value and as of March 31, 2026 and December 31, 2025, there were 13,234,830 outstanding shares of common stock.

Common stock dividend activity for the three months ended March 31, 2026 is summarized in the following table:

---

| | | | | |
|:---|:---|:---|:---|:---|
| <br>**Date Announced** | <br>**Record Date** | <br>**Payment Date** | **Dividend**<br>**Amount**<sup>(1)(2)</sup> | **Dividends**<br>**per Share**<sup>(3)</sup> |
| December 4, 2025 | December 19, 2025 | January 9, 2026 | $10839 | $0.75 |
| February 25, 2026 | March 20, 2026 | April 17, 2026 | $3619 | $0.25 |
| February 25, 2026 | April 20, 2026 | May 15, 2026 | $3619 | $0.25 |
| February 25, 2026 | May 20, 2026 | June 12, 2026 | $3619 | $0.25 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes distributions on outstanding LTIP Units and OP Units.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Dividend amounts for the May and June dividend are estimated based on the outstanding shares of common stock and units as of March 31, 2026.

&nbsp;&nbsp;&nbsp;&nbsp;(3) On February 24, 2026, the Company's Board of Directors approved a transition from a quarterly dividend to a monthly dividend. The dividend rate of $0.75 per share per quarter remains unchanged.

During the three months ended March 31, 2026 and 2025, the Company paid total dividends on its common stock, LTIP Units and OP Units in the aggregate amount of $10,939 and $15,269, respectively.

As of March 31, 2026 and December 31, 2025, the Company had accrued dividend balances of $200 and $216 for dividends payable on the aggregate annual and long-term LTIP Units that are subject to retroactive receipt of dividends on the amount of LTIP Units ultimately earned. During the three months ended March 31, 2026, $83 dividends were accrued and $100 of dividends were paid related to these units. During the three months ended March 31, 2025, $112 of dividends were accrued and $105 of dividends were paid related to these units.

The amount of the dividends paid to the Company's stockholders is determined by the Board and is dependent on a number of factors, including funds available for payment of dividends, the Company's financial condition and capital expenditure requirements, except that, in accordance with the Company's organizational documents and Maryland law, the Company may not make dividend distributions that would: (i) cause it to be unable to pay its debts as they become due in the usual course of business; (ii) cause its total assets to be less than the sum of its total liabilities plus senior liquidation preferences; or (iii) jeopardize its ability to maintain its qualification as a REIT.

On February 24, 2026, the Board approved a transition from a quarterly dividend to a monthly dividend. The monthly dividend will be approved quarterly for each month in the applicable quarter. For the upcoming quarter, the Board declared a monthly common stock cash dividend of $0.25 per share and unit for the months of April, May, and June 2026, payable on April 17, 2026, May 15, 2026, and June 12, 2026, respectively, to stockholders of record as of the close of business on March 20, 2026, April 20, 2026 and May 20, 2026.

*Capital Raising Activity*

In January 2024, the Company and the Operating Partnership implemented a $300 million "at-the-market" equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time to time, shares of its common stock (the "2024 ATM Program"). No shares were sold under the 2024 ATM Program during the three months ended March 31, 2026.

In February 2026, the Company and the Operating Partnership implemented a $75 million "at-the-market" equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time-to-time, shares of its 8.00% Series B Cumulative Redeemable Preferred Stock (the "2026 Series B Preferred ATM Program"). No shares were sold under the 2026 Series B Preferred ATM Program during the three months ended March 31, 2026.

*Common Stock Repurchase Program* 

In August 2025, the Board approved a $50 million common stock repurchase program (the "Stock Repurchase Program"). Under the Stock Repurchase Program, the Company may purchase up to $50 million of its outstanding shares of common stock from time to time in the open market, including through block purchases, through privately negotiated transactions or pursuant to any Rule 10b5-1 trading plan, in accordance with applicable securities laws. The specific timing, price and size of purchases will depend on prevailing stock prices, general economic and market conditions and other considerations. The Stock Repurchase Program does not obligate the Company to repurchase any dollar amount or number of shares of its common stock and may be suspended or discontinued at any time. No shares were repurchased during the three months ended March 31, 2026 and $44 million may yet be purchased under the Stock Repurchase Program. During the year ended December 31, 2025, 175,634 shares or approximately $6 million of the Company's common stock were repurchased under the Stock Repurchase Program.

#### OP Units
During the three months ended March 31, 2026, the Operating Partnership did not issue or redeem any OP Units. During the year ended December 31, 2025, the Operating Partnership did not issue any OP Units and redeemed 5,000 OP Units (adjusted to reflect the impact of the Reverse Stock Split).

The OP Unit value at issuance and redemption is based on the Company's closing share price on the date of the respective transaction and is included as a component of noncontrolling interest equity in the Company's Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025. The Company has sufficient shares of common stock authorized pursuant to its charter to cover the redemption of outstanding OP Units.

#### Note 6 – Related Party Transactions

#### Related Party Balances
The amounts due from related parties as of March 31, 2026 and December 31, 2025 were $177 and $162, respectively. These balances primarily consist of taxes paid on behalf of LTIP Unit and OP Unit holders that are reimbursable to the Company as well as funds owed to the Company from the GII Joint Venture for management fees earned by the Company. The Company had no amounts due to related parties as of March 31, 2026 and December 31, 2025.

#### Note 7 – Stock-Based Compensation

#### 2016 Equity Incentive Plan
The 2016 Equity Incentive Plan, as amended (the "Plan"), is intended to assist the Company and its affiliates in recruiting and retaining employees of the Company, members of the Board, executive officers of the Company, and individuals who provide services to the Company and its affiliates.

The Plan is intended to permit the grant of both qualified and non-qualified options and the grant of stock appreciation rights, restricted stock, unrestricted stock, awards of restricted stock units, performance awards and other equity-based awards (including LTIP Units). Based on the grants outstanding as of March 31, 2026, there were 170,054 shares of common stock that remain available to be granted under the Plan. Units subject to awards under the Plan that are forfeited, cancelled, lapsed, or otherwise expired (excluding shares withheld to satisfy exercise prices or tax withholding obligations) are available for grant.

#### Time-Based Grants
During the three months ended March 31, 2026, the Company granted the following LTIP Units:

---

| | | | |
|:---|:---|:---|:---|
| <br>**Date** | <br>**Description** | **Number of** <br>**Units Issued** |  |
| February 24, 2026 | Final awards under the 2025 Annual Incentive Plan | 33187 |  |
| February 24, 2026 | Time-based awards under the 2026 Long-Term Incentive Plan | 63626 | (1) |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Time-based awards under the 2026 Long-Term Incentive Plan vest upon the third anniversary of the respective grant dates. Vesting may be accelerated under certain circumstances such as a "change-in-control" transaction or a "qualified termination" event.

A detail of the Company's outstanding time-based LTIP Units as of March 31, 2026 is as follows:

---

| | |
|:---|:---|
| Vested units | 592,520 |
| Unvested units | 205,882 |
| &nbsp;&nbsp;LTIP Units outstanding as of March 31, 2026 | 798,402 |

---

**Performance Based Awards**

The Board has approved annual performance-based LTIP awards ("Annual Awards") and long-term performance-based LTIP awards ("Long-Term Awards" and together with the Annual Awards, "Performance Awards") to the executive officers and other employees of the Company. As described below, the Annual Awards have one-year performance periods and the Long-Term Awards have three-year performance periods. In addition to meeting specified performance metrics, vesting in the Performance Awards is subject to service requirements.

A detail of the Performance Awards under the 2024, 2025 and 2026 programs as of March 31, 2026 is as follows:

---

| | |
|:---|:---|
| 2024 Long-Term Awards | 38531 |
| 2025 Long-Term Awards | 32944 |
| 2026 Annual Awards <sup>(1)</sup> | 42221 |
| 2026 Long-Term Awards <sup>(2)</sup> | 60134 |
| Total target Performance Awards as of March 31, 2026 | 173830 |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Approved by the Board on February 24, 2026. The number of target LTIP Units was based on the average closing price of the Company's common stock reported on the New York Stock Exchange over the 15 trading days preceding the award date.

&nbsp;&nbsp;&nbsp;&nbsp;(2) Approved by the Board on February 24, 2026. The number of target LTIP Units was based on the fair value of the Long-Term Awards as determined by an independent valuation consultant *.* See additional detail below.

*Annual Awards*. The Annual Awards are subject to the terms and conditions of LTIP Annual Award Agreements ("LTIP Annual Award Agreements") between the Company and each grantee.

The Compensation Committee of the Board (the "Compensation Committee") and the Board established performance goals for the year ending December 31, 2026, as set forth in the 2026 LTIP Annual Award Agreements (the "Performance Goals") that will be used to determine the number of LTIP Units earned by each grantee. Cumulative stock-based compensation expense during the three months ended March 31, 2026 reflects management's estimate of the probability of the number of these awards that will be earned. As soon as reasonably practicable following the end of the performance period, the Compensation Committee and the Board will determine the extent to which the Company has achieved each of the Performance Goals (expressed as a percentage) and, based on such determination, will calculate the number of LTIP Units that each grantee is entitled to receive. Each grantee may earn up to 150% of the number of his/her target LTIP Units. Any 2026 Annual Award LTIP Units that are not earned will be forfeited and cancelled.

*Vesting.* LTIP Units that are earned as of the end of the applicable performance period will vest in two installments as follows: 50% of the earned LTIP Units will become vested on the valuation date of the awards (which is expected to occur in February 2027) and 50% of the earned LTIP Units become vested on the one year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a "change-in-control" transaction or a "qualified termination" event.

*Distributions.* Distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the estimated number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

*Long-Term Awards.* The Long-Term Awards are subject to the terms and conditions of their related LTIP Long-Term Award Agreements (collectively the "LTIP Long-Term Award Agreements") between the Company and each grantee. The number of LTIP Units that each grantee earns under the LTIP Long-Term Award Agreements will be determined following the conclusion of a three-year performance period based on the Company's (i) total stockholder return ("TSR"), which is determined based on a combination of appreciation in stock price and dividends paid during the performance period, and (ii) relative stockholder return ("RSR"), which is determined by comparing the Company's TSR with the TSRs of the companies that comprise the Dow Jones U.S. Real Estate Health Care Index (the "Index"). Each grantee may earn up to 200% of the number of target LTIP Units covered by the grantee's Long-Term Award. Any target LTIP Units that are not earned will be forfeited and cancelled. The number of LTIP Units earned under the Long-Term Awards will be determined as soon as reasonably practicable following the end of the applicable three-year performance period based on the Company's TSR on an absolute basis (as to 50% of the Long-Term Award) and RSR (as to 50% of the Long-Term Award).

*Vesting.* LTIP Units that are earned as of the end of the applicable three-year performance period will vest in two installments as follows: 50% of the earned LTIP Units will vest upon the day prior to the third anniversary of the respective grant dates and the remaining 50% will vest on the one year anniversary of the initial vesting date. Vesting may be accelerated under certain circumstances such as a "change-in-control" transaction or a "qualified termination" event.

*Distributions.* Pursuant to the LTIP Long-Term Award Agreements, distributions equal to the dividends declared and paid by the Company will accrue during the applicable performance period on the estimated number of LTIP Units that the grantee could earn and will be paid with respect to all of the earned LTIP Units at the conclusion of the applicable performance period, in cash or by the issuance of additional LTIP Units at the discretion of the Compensation Committee.

#### Stock-Based Compensation Expense
Compensation expense for LTIP Unit grants, Annual Awards, and Long-Term Awards is based on the grant date fair value of the units/awards, with no subsequent remeasurement required.

As the Long-Term Awards involve market-based performance conditions, the Company utilizes a Monte Carlo simulation to provide a grant date fair value for expense recognition. The Monte Carlo simulation is a generally accepted statistical technique used, in this instance, to simulate a range of possible future stock prices for the Company and the members of the Index over the Performance Periods. The purpose of this modeling is to use a probabilistic approach for estimating the fair value of the performance share award.

The assumptions used in the Monte Carlo simulation include beginning average stock price, valuation date stock price, expected volatilities, correlation coefficients, risk-free rate of interest, and expected dividend yield. The beginning average stock price is the beginning average stock price for the Company and each member of the Index for the 15 trading days leading up to the grant date of the Long-Term Award. The valuation date stock price is the closing stock price of the Company and each of the peer companies in the Index on the grant dates of the Long-Term Awards. The expected volatilities are modeled using the historical volatilities for the Company and the members of the Index. The correlation coefficients are calculated using the same data as the historical volatilities. The risk-free rate of interest is taken from the U.S. Treasury website and relates to the expected life of the remaining performance period on valuation or revaluation. Lastly, the dividend yield assumption is 0.0%, which is mathematically equivalent to reinvesting dividends in the issuing entity, which is part of the Company's award agreement assumptions.

Below are details regarding certain of the assumptions for the Long-Term Awards using Monte Carlo simulations:

---

| | | | |
|:---|:---|:---|:---|
|  | **2026 Long-Term**<br>**Awards** | **2025 Long-Term**<br>**Awards** | **2024 Long-Term**<br>**Awards** |
| Fair value | $36.96 | $46.60 | $46.85 |
| Target awards  | 60134 | 32944 | 38531 |
| Volatility | 32.31% | 28.67% | 28.12% |
| Risk-free rate | 3.44% | 4.00% | 4.38% |
| Dividend assumption | reinvested | reinvested | reinvested |
| Expected term in years | 3 | 3 | 3 |

---

The Company incurred stock compensation expense of $1,229 and $151 for the three months ended March 31, 2026 and 2025, respectively, related to the grants awarded under the Plan. Compensation expense is included within "General and Administrative" expense in the Company's Condensed Consolidated Statements of Operations.

As of March 31, 2026, total unamortized compensation expense related to these awards of approximately $9.7 million is expected to be recognized over a weighted average remaining period of 2.2 years.

#### Note 8 – Leases
The Company operates as both a lessor and a lessee. As a lessor, the Company is required under ASC Topic 842 to account for leases using an approach that is substantially similar to ASC Topic 840's guidance for operating leases and other leases such as sales-type leases and direct financing leases. In addition, ASC Topic 842 requires lessors to capitalize and amortize only incremental direct leasing costs. As a lessee, the Company is required under the new standard to apply a dual approach, classifying leases, such as ground leases, as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. ASC Topic 842 also requires lessees to record a right of use asset and a lease liability for all leases with an initial term of greater than a year regardless of their classification. The Company has also elected the practical expedient not to recognize right of use assets and lease liabilities for leases with a term of a year or less.

**Information as Lessor** 

To generate positive cash flow, as a lessor, the Company leases its facilities to tenants in exchange for fixed monthly payments that cover rent, property taxes, insurance and certain cost recoveries, primarily common area maintenance ("CAM"). The Company's leases are typically operating leases and generally have initial terms of approximately 5 to 15 years. Payments from the Company's tenants for CAM are considered nonlease components that are separated from lease components and are generally accounted for in accordance with the revenue recognition standard. However, the Company qualified for and elected the practical expedient related to combining the components because the lease component is classified as an operating lease and the timing and pattern of transfer of CAM income, which is not the predominant component, is the same as the lease component, for all asset classes. As such, consideration for CAM is accounted for as part of the overall consideration in the lease. Payments from customers for property taxes and insurance are considered non-components of the lease and therefore no consideration is allocated to them because they do not transfer a good or service to the customer. Fixed contractual payments from the Company's leases are recognized on a straight-line basis over the terms of the respective leases. This means that, with respect to a particular lease, actual amounts billed in accordance with the lease during any given period may be higher or lower than the amount of rental revenue recognized for the period. Straight-line rental revenue is commenced when the tenant assumes control of the leased premises. Accrued straight-line rents receivable represents the amount by which straight-line rental revenue exceeds rents currently billed in accordance with lease agreements.

Some of the Company's leases are subject to annual changes in the Consumer Price Index ("CPI"). Although increases in CPI are not estimated as part of the Company's measurement of straight-line rental revenue, for leases with base rent increases based on CPI, the amount of rent revenue recognized is adjusted in the period the changes in CPI are measured and effective. Additionally, some of the Company's leases have extension options.

Initial direct costs, primarily commissions related to the leasing of our facilities are capitalized when material as incurred. Capitalized leasing costs are amortized on a straight-line basis over the remaining useful life of the respective leases. All other costs to negotiate or arrange a lease are expensed as incurred.

Lease-related receivables, which include accounts receivable and accrued straight-line rents receivable, are reduced for credit losses, if applicable. The Company regularly evaluates the collectability of its lease-related receivables. The Company's evaluation of collectability primarily consists of reviewing past due account balances and considering such factors as the credit quality of our tenant, historical trends of the tenant and changes in tenant payment terms. If the Company's assumptions regarding the collectability of lease-related receivables prove incorrect, the Company could experience credit losses in excess of what was recognized in rental and other revenues.

The Company recognized $38,021 and $34,595 of rental revenue related to operating lease payments for the three months ended March 31, 2026 and 2025, respectively. Of these amounts, $1,592 and $1,793 relate to variable rental revenue for the three months ended March 31, 2026 and 2025, respectively.

The aggregate annual cash to be received by the Company on the noncancelable operating leases related to its portfolio as of March 31, 2026 is as follows for the subsequent years ended December 31:

---

| | |
|:---|:---|
| 2026 (nine months remaining) | $91476 |
| 2027 | 112168 |
| 2028 | 102576 |
| 2029 | 88364 |
| 2030 | 67254 |
| Thereafter | 230301 |
| &nbsp;&nbsp;Total | $692139 |

---

**Information as Lessee**

The Company has 12 buildings located on land that is subject to ground leases with a weighted average remaining term of approximately 43 years. Rental payments on these leases are adjusted periodically based on either the CPI or on a pre-determined schedule. The monthly payments on a pre-determined schedule are recognized on a straight-line basis over the terms of the respective leases. Changes in the CPI are not estimated as part of our measurement of straight-line rental expense. Some of the Company's ground leases contain extension options and, where we determined it was reasonably certain that an extension would occur, they were included in our calculation of the right of use asset and liability. The Company recognized approximately $100 and $77 of ground lease expense during the three months ended March 31, 2026 and 2025, respectively, of which $86 and $46 was paid in cash. The Company incurred interest expense of $66 and $0 from ground leases that were classified as financing leases for the three months ended March 31, 2026 and 2025, respectively.

The following table sets forth the undiscounted cash flows of our scheduled obligations for future lease payments on operating ground leases at March 31, 2026, and a reconciliation of those cash flows to the operating lease liability at March 31, 2026:

---

| | |
|:---|:---|
| 2026 (nine months remaining) | $850 |
| 2027 | 1150 |
| 2028 | 1174 |
| 2029 | 1193 |
| 2030 | 1211 |
| Thereafter | 25988 |
| Total | 31566 |
| Discount | (18228) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease liability | $13338 |

---

**Tenant Concentration**

During the three months ended March 31, 2026, the Company's rental revenues were derived from 310 tenants leasing 189 buildings, and no single tenant exceeded 10% of the Company's rental revenue.

#### Note 9 – Commitments and Contingencies

#### Litigation
The Company is not presently subject to any material litigation nor, to its knowledge, is any material litigation threatened against the Company, which if determined unfavorably to the Company, would have a material adverse effect on the Company's financial position, results of operations, or cash flows.

#### Environmental Matters
The Company follows a policy of monitoring its properties for the presence of hazardous or toxic substances. While there can be no assurance that a material environmental liability does not exist at its properties, the Company is not currently aware of any environmental liability with respect to its properties that would have a material effect on its financial position, results of operations, or cash flows. Additionally, the Company is not aware of any material environmental liability or any unasserted claim or assessment with respect to an environmental liability that management believes would require additional disclosure or the recording of a loss contingency.

**Note 10 – Subsequent Events**

***Contracts to Purchase Seniors Housing Communities***

*The Landing Alexandria*

On May 1, 2026, the Company entered into a purchase agreement with affiliates of Silverstone Senior Living ("SSL") to acquire the Landing Alexandria (the "Landing"), a 163-home, luxury seniors housing community located in Alexandria, Virginia for a purchase price of approximately $130 million. The Landing offers independent living, assisted living and memory care. The Company intends to operate the community as a seniors housing operating property ("SHOP") and to engage an affiliate of Greystone as a third-party manager to manage day-to-day operations. Under this structure, the Company will own the real estate and participate directly in the operating results of the property, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant. It is anticipated that this acquisition will close in the second quarter of 2026. The acquisition is subject to customary closing conditions, including, among other things, the completion of due diligence, licenses and approvals (if any), and other customary conditions. We cannot assure you that the acquisition will be completed on the anticipated terms or timetable, or at all.

*The Riviera at Alexandria*

On May 1, 2026, the Company entered into a purchase agreement with affiliates of SSL to acquire the Riviera at Alexandria (the "Riviera"), a 129-home, luxury independent living community located in Alexandria, Virginia for a purchase price of approximately $119 million. The Company intends to operate the community as a SHOP and to engage an affiliate of Greystone as a third-party manager to manage day-to-day operations. Under this structure, the Company will own the real estate and participate directly in the operating results of the property, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant. It is anticipated that this acquisition will close in the second quarter of 2026. The acquisition is subject to customary closing conditions, including, among other things, the completion of due diligence, licenses and approvals (if any), and other customary conditions. We cannot assure you that the acquisition will be completed on the anticipated terms or timetable, or at all.

*The Pinnacle North Bethesda*

On May 6, 2026, the Company entered into a purchase agreement to acquire the Pinnacle North Bethesda (the "Pinnacle"), a 175-home, luxury seniors housing community with ground floor retail located in North Bethesda, Maryland for a purchase price of approximately $176 million. The Pinnacle offers independent living, assisted living, and memory care housing. The Company intends to operate the community as a SHOP and to engage an affiliate of Greystone as a third-party manager to manage day-to-day operations. Under this structure, the Company will own the real estate and participate directly in the operating results of the property, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant. It is anticipated that this acquisition will close in the fourth quarter of 2026. The acquisition is subject to customary closing conditions, including, among other things, the completion of due diligence, licenses and approvals (if any), and other customary conditions We cannot assure you that the acquisition will be completed on the anticipated terms or timetable, or at all.

***$100 Million Strategic Convertible Perpetual Preferred Equity Investment***

On May 6, 2026 the Company entered into an agreement (the "Investment Agreement") providing for an up to $100 million delayed-draw convertible perpetual preferred equity investment led by Maewyn Capital Partners ("Maewyn"), pursuant to which the Company may sell a total of $100 million of Series C convertible perpetual preferred stock (the "Series C Preferred Stock"), with a liquidation preference of $100 per share, either in full or in multiple tranches within six months from the date of the Investment Agreement. Dividends on the Series C Preferred Stock will accrue at a rate of 6.0% per year and will be payable quarterly in cash. If the Series C Preferred Stock remains outstanding beyond the fourth anniversary of the final draw under the Investment Agreement, the dividend rate will increase by 2.0% annually, up to a maximum of 12.0%. Holders of the Series C Preferred Stock will have the option to convert their shares into shares of the Company's common stock at any time at the then-effective conversion rate (the "Conversion Rate"). The Conversion Rate of the Series C Preferred Stock will initially be set at 2.32558 shares of common stock, based on an implied conversion price of $43.00 per share of common stock. Three years after the final draw, the Company has the option to convert the Series C Preferred Stock to common stock if the volume-weighted average price of its common stock exceeds 120.0% of the conversion price for 45 consecutive trading days.

The Company may redeem the Series C Convertible Preferred Stock at par at any time, after the fourth anniversary of the final draw under the Investment Agreement. If the Series C Convertible Preferred Stock is redeemed, the Company will issue a warrant (each, a "Warrant") to each holder of shares of Series C Preferred Stock that is redeemed. Each Warrant will represent a holder's right to purchase, at an exercise price equal to the conversion price for the Series C Preferred Stock as of the business day before the applicable redemption date, a number of shares of common stock equal to the aggregate liquidation preference of the shares of Series C Preferred

Stock of such holder to be redeemed divided by the conversion price of the Series C Preferred Stock as of the business day before the applicable redemption date. Each Warrant will be exercisable by the holder thereof, in whole or in part, at any time, or from time to time, prior to the fifth anniversary of the issuance of such Warrant.

Additionally, so long as Maewyn or its affiliates beneficially own at least 5.0% of the Company's common stock on a fully-diluted basis, Maewyn will have the right to nominate one designee to be appointed as a member of the Board. The initial designee, Charles Fitzgerald, Managing Partner of Maewyn, will be appointed to the Company's Board following the Company's 2026 Annual Meeting of Stockholders on May 20, 2026.

***Common Dividend Modification***

On May 5, 2026, the Board declared a monthly common stock cash dividend of $0.16 per share for each of July, August and September of 2026, representing quarterly cash dividends totaling $0.48 per share. This compares to a monthly common stock cash dividend of $0.25 per share for April, May and June 2026, and represents an approximate 36% reduction. The Company is resizing its dividend to focus on retaining cash flow and to accelerate the Company's acquisition strategy and accelerate the ramp of its SHOP portfolio.

***Mezzanine Loan***

On April 1, 2026, the Company closed a $3.0 million mezzanine loan secured by an under-development medical facility located in Fort Myers, Florida. The medical facility is an on-campus outpatient surgical facility that is 100% pre-leased to an investment-grade tenant under a 15-year lease with no termination rights. The loan bears interest at a rate of 12.0% per annum, has an initial term of 24 months, and represents approximately 10% of the total project cost. In connection with the loan, the Company holds a right of first offer and right of first refusal with respect to a sale of the property, which are subject to the pre-leased tenant's corresponding rights.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*The following discussion should be read in conjunction with our financial statements, including the notes to those financial statements, included elsewhere in this Quarterly Report on Form 10-Q (this "Report"). Some of the statements we make in this section are forward-looking statements within the meaning of the federal securities laws. For a complete discussion of forward-looking statements, see the section below entitled "Special Note Regarding Forward-Looking Statements." Certain risk factors may cause actual results, performance, or achievements to differ materially from those expressed or implied by the following discussion. For a discussion of such risk factors, see Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2025 (the "2025 Annual Report"), that was filed with the U.S. Securities and Exchange Commission (the "SEC" or the "Commission") on March 2, 2026 and Item 1A. Risk Factors in this Quarterly Report on Form 10-Q. Unless otherwise indicated, all dollar amounts in the following discussion are presented in thousands.*

**Special Note Regarding Forward-Looking Statements** 

This Report contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act")). In particular, statements pertaining to our investment in our Series C Preferred Stock or the terms of the investment agreement by Maewyn Capital Partners and its affiliates, future Board composition, trends, liquidity, capital resources, future dividends, and the healthcare industry and the healthcare real estate markets and opportunity, among others, contain forward-looking statements. You can identify forward-looking statements by the use of forward-looking terminology including, but not limited to, "believes," "expects," "may," "will," "should," "seeks," "approximately," "intends," "plans," "estimates" or "anticipates" or the negative of these words and phrases or similar words or phrases which are predictions of or indicate future events or trends and which do not relate solely to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions.

Forward-looking statements involve numerous risks and uncertainties and you should not rely on them as predictions of future events. Forward-looking statements depend on assumptions, data or methods which may be incorrect or imprecise and we may not be able to realize them. We do not guarantee that the transactions and events described will happen as described (or that they will happen at all). The following factors, among others, could cause actual results and future events to differ materially from those set forth or contemplated in the forward-looking statements:

● difficulties in identifying healthcare and seniors housing facilities to acquire (due to increased cost of capital, competition or otherwise) and completing such acquisitions;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● defaults on or non-renewal of leases by tenants;

● our ability to collect rents;

● increases in interest rates and increased operating costs;

● macroeconomic and geopolitical factors, including, but not limited to, inflationary pressures, tariffs and international trade policies, elevated interest rates, distress in the banking sector, global supply chain disruptions and ongoing geopolitical conflicts and war;

● changes in current healthcare and healthcare real estate trends and costs, including wage inflation;

● an epidemic or pandemic (such as the COVID-19 epidemic), and the measures that international, federal, state and local governments, agencies, law enforcement and/or health authorities implement to address it;

● our ability to satisfy the covenants in our existing and any future debt agreements;

● our ability to refinance our existing debt when needed or on favorable terms;

● decreased rental rates or increased vacancy rates, including expected rent levels on acquired properties;

● adverse economic or real estate conditions or developments, either nationally or in the markets in which our facilities are located;

● our failure to generate sufficient cash flows to service our outstanding obligations;

● our ability to satisfy our short and long-term liquidity requirements;

● our ability to deploy the debt and equity capital we raise;

● our ability to hedge our interest rate risk;

● our ability to raise additional equity and debt capital on attractive terms or at all;

● our ability to make distributions on shares of our common and preferred stock or to redeem our preferred stock;

● expectations regarding the timing and/or completion of any acquisition;

● expectations regarding the timing and/or completion of dispositions, and the expected use of proceeds therefrom;

● our use of joint ventures may limit our returns on and our flexibility with jointly-owned investments;

● general volatility of the market price of our common and preferred stock;

● changes in our business or our investment or financing strategy;

● our dependence upon key personnel, whose continued service is not guaranteed;

● our ability to identify, hire and retain highly qualified personnel in the future;

● the degree and nature of our competition;

● changes in healthcare laws, governmental regulations, tax laws and similar matters;

● changes in expected trends in Medicare, Medicaid and commercial insurance reimbursement trends, including changes in Medicaid reimbursement rates pursuant to the One Big Beautiful Bill Act (the "OBBBA");

● competition for investment opportunities;

● our failure to achieve the anticipated benefits from, and effectively integrate, our completed or anticipated acquisitions and investments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● our expected capital and tenant improvement expenditures;

● changes in accounting policies generally accepted in the United States of America ("GAAP");

● lack of, or insufficient amounts of, insurance;

● other factors affecting the real estate industry generally;

● changes in the tax treatment of our distributions;

● our failure to maintain our qualification as a real estate investment trust ("REIT") for U.S. federal income tax purposes;

● our ability to qualify for the safe harbor from the 100% prohibited transactions tax under the REIT rules with respect to our property dispositions; and

● limitations imposed on our business due to, and our ability to satisfy, complex rules relating to REIT qualification for U.S. federal income tax purposes.

See Item 1A. Risk Factors in our 2025 Annual Report and Item 1A. Risk Factors in this Quarterly Report on Form 10-Q for further discussion of these and other risks, as well as the risks, uncertainties and other factors discussed in this Report and identified in other documents we may file with the SEC from time to time. You should carefully consider these risks before making any investment decisions in our company. New risks and uncertainties may also emerge from time to time that could materially and adversely affect us. While forward-looking statements reflect our good faith beliefs, they are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes after the date of this Report, except as required by applicable law. You should not place undue reliance on any forward-looking statements that are based on information currently available to us or the third parties making the forward-looking statements.

**Overview**

Chiron Real Estate Inc. (the "Company," "us," "we," or "our") is a Maryland corporation and internally managed REIT that acquires (i) healthcare facilities leased to physician groups and regional and national healthcare systems and (ii) seniors housing communities. We hold our facilities and conduct our operations through a Delaware limited partnership subsidiary, Chiron Real Estate LP (the "Operating Partnership"). Our wholly owned subsidiary, Chiron Real Estate GP LLC, is the sole general partner of our Operating Partnership and, as of March 31, 2026, we owned 91.4% of the outstanding common operating partnership units ("OP Units"), with the remaining 8.6% owned by holders of long-term incentive plan units ("LTIP Units") and third-party limited partners who contributed properties or services to the Operating Partnership in exchange for OP Units.

Our revenues are derived from the rental and operating expense reimbursement payments we receive from our tenants, and most of our leases are medium to long-term triple net leases with contractual rent escalation provisions. Our primary expenses are depreciation, interest, and general and administrative expenses. We finance our acquisitions with a mixture of debt and equity primarily from our cash from operations, borrowings under our Credit Facility, and stock issuances.

On September 19, 2025, the Company completed a one-for-five reverse stock split of its outstanding shares of common stock, with a corresponding adjustment to the outstanding partnership units of the Operating Partnership (the "Reverse Stock Split"). Unless otherwise noted, all common share and unit amounts shown herein are shown on a split-adjusted basis.

**Business Overview and Strategy** 

Our business strategy is to invest primarily in healthcare properties that provide an attractive rate of return relative to our cost of capital and are operated by profitable physician groups, regional or national healthcare systems or combinations thereof. We believe this strategy allows us to attain our goals of providing stockholders with (i) attractive dividends and (ii) stock price appreciation. To implement this strategy, we seek to invest:

● in off-campus medical facilities and other decentralized components of the healthcare delivery system because we believe that healthcare delivery trends in the U.S. are increasingly moving away from centralized hospital locations;

● in small to mid-sized healthcare facilities located in secondary markets and suburbs of primary markets and that provide services needed for an aging population, such as cardiovascular treatment, rehabilitation, eye surgery, gastroenterology,

oncology treatment and orthopedics. We believe these facilities and markets are typically overlooked by larger REITs and other healthcare investors but contain tenant credit profiles that are like those of larger, more expensive facilities in primary markets; and

● active adult and other seniors residential facilities that are located in attractive markets.

Most of our healthcare facilities are leased to single-tenants under triple-net leases. Our portfolio also contains some multi-tenant properties with gross lease or modified gross lease structures. In addition, as of March 31, 2026, we had an interest in two unconsolidated joint ventures that own healthcare facilities.

**Our Properties**

As of March 31, 2026, we had gross investments of approximately $1.5 billion in real estate, consisting of 189 buildings with an aggregate of approximately 5.1 million leasable square feet and approximately $118.2 million of annualized base rent. This data does not include amounts for properties held in our unconsolidated joint ventures.

***2026 Investment Activity***

On January 6, 2026, the Company entered into a joint venture with a developer to facilitate the development of a 132-unit, active adult residential community in a suburb of Minneapolis, Minnesota (the "Active Adult Joint Venture"). We invested $7.1 million for a 49% equity interest in the Active Adult Joint Venture, with the developer retaining a 51% interest. The Active Adult Joint Venture

entered into a construction loan with a principal balance of $31.0 million. The developer is serving as the managing member of the Active Adult Joint Venture. We account for our interest in the Joint Venture using the equity method of accounting.

**Recent Developments**

***Contracts to Purchase Seniors Housing Communities***

*The Landing Alexandria*

On May 1, 2026, the Company entered into a purchase agreement with affiliates of Silverstone Senior Living ("SSL") to acquire the Landing Alexandria (the "Landing"), a 163-home, luxury seniors housing community located in Alexandria, Virginia for a purchase price of approximately $130 million. The Landing offers independent living, assisted living and memory care. The Company intends to operate the community as a seniors housing operating property ("SHOP") and to engage an affiliate of Greystone as a third-party manager to manage day-to-day operations. Under this structure, the Company will own the real estate and participate directly in the operating results of the property, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant. It is anticipated that this acquisition will close in the second quarter of 2026. The acquisition is subject to customary closing conditions, including, among other things, the completion of due diligence, licenses and approvals (if any), and other customary conditions. We cannot assure you that the acquisition will be completed on the anticipated terms or timetable, or at all.

*The Riviera at Alexandria*

On May 1, 2026, the Company entered into a purchase agreement with affiliates of SSL to acquire the Riviera at Alexandria (the "Riviera"), a 129-home, luxury independent living community located in Alexandria, Virginia for a purchase price of approximately $119 million. The Company intends to operate the community as a SHOP and to engage an affiliate of Greystone as a third-party manager to manage day-to-day operations. Under this structure, the Company will own the real estate and participate directly in the operating results of the property, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant. It is anticipated that this acquisition will close in the second quarter of 2026. The acquisition is subject to customary closing conditions, including, among other things, the completion of due diligence, licenses and approvals (if any), and other customary conditions. We cannot assure you that the acquisition will be completed on the anticipated terms or timetable, or at all.

*The Pinnacle North Bethesda*

On May 6, 2026, the Company entered into a purchase agreement to acquire the Pinnacle North Bethesda (the "Pinnacle"), a 175-home, luxury seniors housing community with ground floor retail located in North Bethesda, Maryland for a purchase price of approximately $176 million. The Pinnacle offers independent living, assisted living, and memory care housing. The Company intends to operate the community as a SHOP and to engage an affiliate of Greystone as a third-party manager to manage day-to-day operations. Under this structure, the Company will own the real estate and participate directly in the operating results of the property, including revenues and operating expenses, rather than receiving fixed lease payments from a third-party tenant. It is anticipated that this

acquisition will close in the fourth quarter of 2026. The acquisition is subject to customary closing conditions, including, among other things, the completion of due diligence, licenses and approvals (if any), and other customary conditions We cannot assure you that the acquisition will be completed on the anticipated terms or timetable, or at all.

***$100 Million Strategic Convertible Perpetual Preferred Equity Investment***

On May 6, 2026 the Company entered into an agreement (the "Investment Agreement") providing for an up to $100 million delayed-draw convertible perpetual preferred equity investment led by Maewyn Capital Partners ("Maewyn"), pursuant to which the Company may sell a total of $100 million of Series C convertible perpetual preferred stock (the "Series C Preferred Stock"), with a liquidation preference of $100 per share, either in full or in multiple tranches within six months from the date of the Investment Agreement. Dividends on the Series C Preferred Stock will accrue at a rate of 6.0% per year and will be payable quarterly in cash. If the Series C Preferred Stock remains outstanding beyond the fourth anniversary of the final draw under the Investment Agreement, the dividend rate will increase by 2.0% annually, up to a maximum of 12.0%. Holders of the Series C Preferred Stock will have the option to convert their shares into shares of the Company's common stock at any time at the then-effective conversion rate (the "Conversion Rate"). The Conversion Rate of the Series C Preferred Stock will initially be set at 2.32558 shares of common stock, based on an implied conversion price of $43.00 per share of common stock. Three years after the final draw, the Company has the option to convert the Series C Preferred Stock to common stock if the volume-weighted average price of its common stock exceeds 120.0% of the conversion price for 45 consecutive trading days.

The Company may redeem the Series C Convertible Preferred Stock at par at any time, after the fourth anniversary of the final draw under the Investment Agreement. If the Series C Convertible Preferred Stock is redeemed, the Company will issue a warrant (each, a "Warrant") to each holder of shares of Series C Preferred Stock that is redeemed. Each Warrant will represent a holder's right to purchase, at an exercise price equal to the conversion price for the Series C Preferred Stock as of the business day before the applicable redemption date, a number of shares of common stock equal to the aggregate liquidation preference of the shares of Series C Preferred Stock of such holder to be redeemed divided by the conversion price of the Series C Preferred Stock as of the business day before the applicable redemption date. Each Warrant will be exercisable by the holder thereof, in whole or in part, at any time, or from time to time, prior to the fifth anniversary of the issuance of such Warrant.

Additionally, so long as Maewyn or its affiliates beneficially own at least 5.0% of the Company's common stock on a fully-diluted basis, Maewyn will have the right to nominate one designee to be appointed as a member of the Board. The initial designee, Charles Fitzgerald, Managing Partner of Maewyn, will be appointed to the Company's Board following the Company's 2026 Annual Meeting of Stockholders on May 20, 2026.

***Common Dividend Modification***

On May 5, 2026, the Board declared a monthly common stock cash dividend of $0.16 per share for each of July, August and September of 2026, representing quarterly cash dividends totaling $0.48 per share. This compares to a monthly common stock cash dividend of $0.25 per share for April, May and June 2026, and represents an approximate 36% reduction. The Company is resizing its dividend to focus on retaining cash flow and to accelerate the Company's acquisition strategy and accelerate the ramp of its SHOP portfolio.

***Mezzanine Loan***

On April 1, 2026, the Company closed a $3.0 million mezzanine loan secured by an under-development medical facility located in Fort Myers, Florida. The medical facility is an on-campus outpatient surgical facility that is 100% pre-leased to an investment-grade tenant under a 15-year lease with no termination rights. The loan bears interest at a rate of 12.0% per annum, has an initial term of 24 months, and represents approximately 10% of the total project cost. In connection with the loan, the Company holds a right of first offer and right of first refusal with respect to a sale of the property, which are subject to the pre-leased tenant's corresponding rights.

***Chapter 11 Reorganization Filing of White Rock Medical Center, LLC***

On January 20, 2026, White Rock Medical Center LLC, filed for Chapter 11 bankruptcy protection under the United States Bankruptcy Code. At the time of its bankruptcy filing, White Rock operated two hospitals in Texas, including the White Rock Medical Center in Dallas, Texas, an acute-care hospital owned by the Company where White Rock is the sole tenant and has been operating the hospital since October 2023. There are 12 years remaining on this lease. According to the filed bankruptcy documents, the primary reason for the bankruptcy is a dispute with the former operator of the facility related to amounts due to the former operator. Accordingly White Rock plans to (i) restructure indebtedness related to its purchase of the hospital operations at the White Rock Medical Center and a related transition services agreement and (ii) sell its hospital operations to a third party, with the goal of stabilizing its operations and maximizing value to its stakeholders. As a means of assisting White Rock in its stabilization efforts, the Company has funded annual

property tax obligations due under the lease and accepted reduced monthly payments. As of May 5, 2026, the Company has a receivable balance, net of security deposits, of approximately $1.5 million (exclusive of late fees and interest thereon). Although we expect White Rock to affirm our lease as part of its reorganization plan, as of May 5, 2026, no reorganization plan has been filed with the courts and there can be no assurance that White Rock will affirm its lease with us or that we will receive any amounts owed to us.

**Trends Which May Influence Our Results of Operations** 

We believe the following trends may positively impact our results of operations:

● *An aging population*. The general aging of the population, driven by the large baby boomer generation (born 1946-1964) and increases in life expectancy due to advances in medical technology and services, continues to be a key driver of growth in healthcare expenditures. According to the most recent U.S. Census Bureau estimates, the population age 65 and older grew by over a third during the past decade, and roughly 3.1% from 2023 to 2024. We believe this segment of the U.S. population will utilize many of the services provided at our healthcare facilities such as orthopedics, cardiac, gastroenterology and rehabilitation.

● *Seniors housing communities.* As occupancy continues to recover in many markets and new supply remains constrained, owners of seniors housing properties have generally seen improving profitability and greater pricing power, including the ability to increase resident fees and reduce concessions. Margin recovery remains influenced by labor availability and wage pressure, as well as elevated insurance and other operating costs; accordingly, community performance tends to be strongest at well-located assets with experienced operators and favorable payer/resident mix.

● *A continuing shift towards outpatient care*. According to the American Hospital Association, patients are demanding more outpatient operations. We believe this shift in patient preference from inpatient to outpatient facilities will benefit our tenants as most of our properties consist of outpatient facilities.

● *Physician practice group and hospital consolidation*. We believe the trend towards physician group consolidation will serve to strengthen the credit quality of our tenants if our tenants merge or are consolidated with larger health systems.

We believe the following trends may negatively impact our results of operations:

● *Interest rates remain at elevated levels.* During 2025, the U.S. Federal Reserve (the "Fed") continued lowering the Federal Funds Rate with the most recent cut in December 2025 bringing the target range to 3.50% to 3.75%, a level that remains unchanged through March 31, 2026. The 10-Year U.S. Treasury yield and Secured Overnight Financing Rate ("SOFR") increased modestly during the first quarter of 2026, with the 10-year U.S. Treasury yield and one-month term SOFR at 4.30% and 3.67% as of March 31, 2026, respectively. Although interest rates trended lower during 2025, interest rates are significantly higher than in 2021, when we entered into interest rate swaps with respect to the $350 million Term Loan A component of our Credit Facility. These interest rate swaps fixed the SOFR component of our interest rate on our Term Loan A at 1.36%; however, these swaps expired in April 2026 (the original maturity date of Term Loan A). In October 2025, we entered into $350 million of new forward-starting interest rate swaps that became effective in May 2026 to fully hedge the SOFR components of the new three Term Loan A tranches in the Credit Facility through their respective maturities at rates ranging from 3.24% to 3.32%. The current elevated interest rate environment has already resulted in material increases in our interest expense with respect to our floating-rate indebtedness and, beginning in May 2026, will materially increase our interest expense with respect to our fixed-rate indebtedness.

● *Increased Cost of Healthcare Delivery*. Healthcare delivery costs continue to increase due to, among other things, increases in labor costs, medical supplies and technology investments. Increases in the cost of healthcare delivery can put stress on our tenants' business, which, if not offset by revenue increases, could negatively affect our tenants' ability to pay rent to us.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

● *Changes in third party reimbursement methods and policies*. The price of healthcare services has been increasing, and, as a result, we believe that third-party payors, such as Medicare and commercial insurance companies, will continue to scrutinize and reduce the types of healthcare services eligible for, and the amounts of, reimbursement under their health insurance plans or increase the portion of premiums for which covered individuals are responsible. In January 2026, CMS announced proposed rate increases for 2027 to Medicare Advantage health plans of less than a tenth of a percent, which was less than market expectations. If finalized, this modest rate increase could result in benefit cuts or higher premiums for Medicare Advantage participants. Additionally, beginning on January 1, 2026, premium tax credits that were intended to assist certain participants on the healthcare insurance exchanges in purchasing health insurance expired, which could result in significant premium increases for these participants. If these trends continue, our tenants' businesses will continue to be negatively affected, which may impact their ability to pay rent to us.

**Critical Accounting Estimates**

The preparation of financial statements in conformity with GAAP requires our management to use judgment in the application of accounting policies, including making estimates and assumptions. We base estimates on the best information available to us at the time, our experience and on various other assumptions believed to be reasonable under the circumstances. These estimates affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. If our judgment or interpretation of the facts and circumstances relating to various transactions or other matters had been different, it is possible that different accounting would have been applied, resulting in a different presentation of our financial statements. From time to time, we re-evaluate our estimates and assumptions. In the event estimates or assumptions prove to be different from actual results, adjustments are made in subsequent periods to reflect more current estimates and assumptions about matters that are inherently uncertain. Please refer to our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on March 2, 2026, for further information regarding the critical accounting policies that affect our more significant estimates and judgments used in the preparation of our condensed consolidated financial statements included in Part I, Item 1 of this Report.

**Consolidated Results of Operations** 

***Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | |
|  | **2026** | **2025** | <br>**$ Change** |
|  | (in thousands) | (in thousands) |  |
| **Revenue** |  |  |  |
| Rental revenue | $38021 | $34595 | $3426 |
| Other income | 43 | 23 | 20 |
| &nbsp;&nbsp;Total revenue | 38064 | 34618 | 3446 |
| **Expenses** |  |  |  |
| General and administrative | 5089 | 3620 | 1469 |
| Operating expenses | 9250 | 7585 | 1665 |
| Depreciation expense | 11087 | 10307 | 780 |
| Amortization expense | 3740 | 3520 | 220 |
| Interest expense | 7233 | 7167 | 66 |
| &nbsp;&nbsp;Total expenses | 36399 | 32199 | 4200 |
| &nbsp;&nbsp;Income before other income (expense) | 1665 | 2419 | (754) |
| &nbsp;&nbsp;Gain on sale of investment properties |  | 1358 | (1358) |
| &nbsp;&nbsp;Equity loss from unconsolidated joint ventures | (11) | (40) | 29 |
| &nbsp;&nbsp;Net income  | $1654 | $3737 | $(2083) |

---

***Revenue***

***Total Revenue***

Total revenue for the three months ended March 31, 2026 was $38.1 million, compared to $34.6 million for the same period in 2025, representing an increase of $3.5 million. The increase was primarily driven by rental revenue from properties acquired after March 31, 2025, as well as the recognition of a full three months of rental revenue in 2026 from acquisitions completed during the three months ended March 31, 2025. These increases, together with growth in our existing portfolio, were partially offset by the impact of

dispositions completed during the same period. Within that increase, $6.3 million in revenue was recognized from net lease expense recoveries during the three months ended March 31, 2026, compared to $5.2 million for the same period in 2025.

***Expenses***

***General and Administrative***

General and administrative expenses for the three months ended March 31, 2026 were $5.1 million, compared to $3.6 million for the same period in 2025, an increase of $1.5 million. The increase was primarily driven by an increase in non-cash LTIP compensation expense of $1.1 million, other compensation and benefits of $0.2 million, and general corporate expenses of $0.2 million.

***Operating Expenses***

Operating expenses for the three months ended March 31, 2026 were $9.3 million, compared to $7.6 million for the same period in 2025, an increase of $1.7 million. The increase was primarily attributable to portfolio growth, including operating expenses from facilities acquired after March 31, 2025 and the inclusion of a full three months of operating expenses in 2026 for acquisitions completed during the three months ended March 31, 2025. Operating expenses in the existing portfolio also increased, reflecting higher property-level costs year over year. These increases were partially offset by the impact of dispositions completed during the same period. Included in these amounts were $6.3 million of recoverable property operating expenses incurred during the three months ended March 31, 2026, compared to $5.2 million for the same period in 2025.

***Depreciation Expense***

Depreciation expense for the three months ended March 31, 2026 was $11.1 million, compared to $10.3 million for the same period in 2025, an increase of $0.8 million. The increase was primarily driven by properties acquired after March 31, 2025, as well as the recognition of a full three months of depreciation expense in 2026 from acquisitions completed during the three months ended March 31, 2025, partially offset by dispositions during that same period.

***Amortization Expense***

Amortization expense for the three months ended March 31, 2026 was $3.7 million, compared to $3.5 million for the same period in 2025, an increase of $0.2 million. The increase was primarily driven by properties acquired after March 31, 2025, as well as the recognition of a full three months of amortization expense in 2026 from acquisitions completed during the three months ended March 31, 2025, partially offset by dispositions and decreases on the existing portfolio during that same period.

***Interest Expense***

Interest expense for the three months ended March 31, 2026 was $7.2 million, compared to $7.2 million for the same period in 2025. While rates declined from 2025 to 2026, the decrease in interest expense was partially offset by increases due to higher average borrowings during the three months ended March 31, 2026, compared to the same period in 2025.

The weighted average interest rate of our debt for the three months ended March 31, 2026 was 3.72% compared to 3.83% for the same period in 2025. Additionally, the weighted average interest rate and term of our debt was 3.58% and 3.9 years, respectively, at March 31, 2026, compared to 3.84% and 1.8 years, respectively, at March 31, 2025.

***Income Before Other Income (Expense)***

Income before other income (expense) for the three months ended March 31, 2026 was $1.7 million, compared to $2.4 million for the same period in 2025, a decrease of $0.7 million.

***Gain on Sale of Investment Properties***

During the three months ended March 31, 2026, we had no property dispositions. During the three months ended March 31, 2025, we completed two dispositions resulting in an aggregate gain of $1.4 million.

***Equity Loss from Unconsolidated Joint Ventures***

Equity Loss from Unconsolidated Joint Ventures for the three months ended March 31, 2026 was $11 thousand, compared to $40 thousand for the same period in 2025, a decrease of $29 thousand.

***Net Income***

Net income for the three months ended March 31, 2026 was $1.7 million, compared to net income of $3.7 million for the same period in 2025, a decrease of $2.0 million.

**Assets and Liabilities** 

As of March 31, 2026 and December 31, 2025 our principal assets consisted of investments in real estate, net, of $1.1 billion and $1.2 billion, respectively. We completed no acquisitions or dispositions during the three months ended March 31, 2026. Our liquid assets consisted primarily of cash and cash equivalents and restricted cash of $10.9 million and $11.9 million, as of March 31, 2026 and December 31, 2025, respectively.

The decrease in our cash and cash equivalents and restricted cash balances to $10.9 million as of March 31, 2026, compared to $11.9 million as of December 31, 2025, was primarily due to funds used to invest in the Active Adult Joint Venture, the payment of our first Series B Preferred stock dividend, funds used for capital expenditures on existing real estate investments, and leasing commissions, partially offset by net borrowings on our Credit Facility, and net cash provided by operating activities.

The increase in our total liabilities to $717.4 million as of March 31, 2026 compared to $712.4 million as of December 31, 2025, was primarily the result of higher net borrowings outstanding on our Credit Facility, partially offset by a lower accounts payable and accrued expenses.

***Cash Flow Information***

***Three Months Ended March 31, 2026 Compared to Three Months Ended March 31, 2025***

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  | |
|  | **2026** | **2025** | <br>**$ Change** |
|  | (in thousands) | (in thousands) |  |
| Cash provided by operating activities | $13352 | $12272 | $1080 |
| Cash used in investing activities | (9842) | (27224) | 17382 |
| Cash (used in) provided by financing activities | (4439) | 13598 | (18037) |
| &nbsp;&nbsp;Decrease in cash and cash equivalents and restricted cash | $(929) | $(1354) | $425 |

---

Net cash provided by operating activities for the three months ended March 31, 2026 was $13.4 million, compared to $12.3 million for the same period in 2025. Net cash provided by operating activities increased primarily due to the impact of our 2025 acquisitions.

Net cash used in investing activities for the three months ended March 31, 2026 was $9.8 million, compared to $27.2 million for the same period in 2025. Net cash used in investing activities decreased primarily due to higher acquisition activity in 2025 compared to 2026.

Net cash used in financing activities for the three months ended March 31, 2026 was $4.4 million, compared to net cash provided by financing activities of $13.6 million for the same period in 2025. This change in cash flow is primarily due to lower net borrowings on our Credit Facility, and lower dividend payments to common and preferred stockholders as well as holders of OP Units and LTIP Units.

**Non-GAAP Financial Measures**

Management considers certain non-GAAP financial measures to be useful supplemental measures of the Company's operating performance. A non-GAAP financial measure is generally defined as one that purports to measure financial performance, financial position or cash flows, but excludes or includes amounts that would not be so adjusted in the most comparable measure determined in accordance with GAAP. The Company reports non-GAAP financial measures because these measures are observed by management to also be among the most predominant measures used by the REIT industry and by industry analysts to evaluate REITs. For these reasons, management deems it appropriate to disclose and discuss these non-GAAP financial measures. Set forth below are descriptions of the non-GAAP financial measures management considers relevant to the Company's business and useful to investors, as well as reconciliations of those measures to the most directly comparable GAAP financial measure.

The non-GAAP financial measures presented herein are not necessarily identical to those presented by other real estate companies due to the fact that not all real estate companies use the same definitions. These measures should not be considered as alternatives to net income, as indicators of the Company's financial performance, or as alternatives to cash flow from operating activities as measures of the Company's liquidity, nor are these measures necessarily indicative of sufficient cash flow to fund all of the Company's needs. Management believes that in order to facilitate a clear understanding of the Company's historical consolidated operating results, these measures should be examined in conjunction with net income and cash flows from operations as presented in the Condensed Consolidated Financial Statements and other financial data included elsewhere in this Report.

*Funds from Operations, Core Funds from Operations, and Funds Available for Distribution*

Funds from operations attributable to common stockholders and noncontrolling interest ("FFO"), and core FFO attributable to common stockholders and noncontrolling interest ("Core FFO") and funds available for distribution attributable to common stockholders and noncontrolling interest ("FAD") are non-GAAP financial measures within the meaning of the rules of the SEC. The Company considers FFO, Core FFO, and FAD to be important supplemental measures of its operating performance and believes FFO is frequently used by securities analysts, investors, and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results.

In accordance with the National Association of Real Estate Investment Trusts' ("NAREIT") definition, FFO means net income or loss computed in accordance with GAAP before noncontrolling interests of holders of OP Units and LTIP Units, excluding gains (or losses) from sales of property and extraordinary items, property impairment losses, less preferred stock dividends, plus real estate-related depreciation and amortization (excluding amortization of debt issuance costs and the amortization of above and below market leases), and after adjustments for unconsolidated partnerships and joint ventures calculated to reflect FFO on the same basis. Because FFO excludes real estate-related depreciation and amortization (other than amortization of debt issuance costs and above and below market lease amortization expense), the Company believes that FFO provides a performance measure that, when compared period-over-period, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from the closest GAAP measurement, net income or loss.

Core FFO is a non-GAAP measure used by many investors and analysts to measure a real estate company's operating performance by removing the effect of items that do not reflect ongoing property operations. Management calculates Core FFO by modifying the NAREIT computation of FFO by adjusting it for certain cash and non-cash items and certain recurring and non-recurring items. For the Company these items include recurring acquisition and disposition costs, loss on the extinguishment of debt, recurring straight line deferred rental revenue, recurring stock-based compensation expense, recurring amortization of above and below market leases, recurring amortization of debt issuance costs, severance and transition related expense, costs related to our reverse stock split, and other items related to unconsolidated partnerships and joint ventures.

We calculate FAD by subtracting from Core FFO capital expenditures, including tenant improvements, leasing commissions and building capital. Management believes FAD is useful in analyzing the portion of cash flow that is available for distribution to stockholders and unitholders. Investors, analysts and the Company utilize FAD as an indicator of common dividend potential.

Management believes that reporting Core FFO in addition to FFO and FAD is a useful supplemental measure for the investment community to use when evaluating the operating performance of the Company on a comparative basis.

A reconciliation of net income to FFO and Core FFO and FAD for the three months ended March 31, 2026 and 2025 is as follows. All per share, per share and unit, and weighted average share and unit amounts have been adjusted to reflect the impact of the Reverse Stock Split.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
| **Net income**  | $**1654** | $**3737** |
| Less: Preferred stock dividends | (2473) | (1455) |
| Depreciation and amortization expense | 14802 | 13806 |
| Depreciation and amortization expense from unconsolidated joint ventures | 73 | 49 |
| Gain on sale of investment properties |  | (1358) |
| &nbsp;&nbsp;**FFO attributable to common stockholders and noncontrolling interest** | $**14056** | $**14779** |
| Amortization of above market leases, net | 146 | 452 |
| Straight line deferred rental revenue | (204) | (57) |
| Stock-based compensation expense | 1229 | 151 |
| Amortization of debt issuance costs and other | 807 | 559 |
| Severance and transition related expense |  | 104 |
| Other adjustments from unconsolidated joint ventures | (19) | 31 |
| &nbsp;&nbsp;**Core FFO attributable to common stockholders and noncontrolling interest** | $**16015** | $**16019** |
| **Net (loss) income attributable to common stockholders per share – basic and diluted** | $**(0.06)** | $**0.16** |
| **FFO attributable to common stockholders and noncontrolling interest per share and unit** | $**0.97** | $**1.02** |
| **Core FFO attributable to common stockholders and noncontrolling interest per share and unit** | $**1.11** | $**1.11** |
| Weighted Average Shares and Units Outstanding – basic and diluted | 14429 | 14475 |
| **Weighted Average Shares and Units Outstanding:** |  |  |
| Weighted Average Common Shares | 13235 | 13375 |
| Weighted Average OP Units | 444 | 449 |
| Weighted Average LTIP Units | 750 | 651 |
| Weighted Average Shares and Units Outstanding – basic and diluted | 14429 | 14475 |
| **Core FFO attributable to common stockholders and noncontrolling interest** | $**16015** | $**16019** |
| Tenant improvements | (594) | (704) |
| Leasing commissions | (550) | (115) |
| Building capital | (1550) | (1907) |
| &nbsp;&nbsp;**FAD attributable to common stockholders and noncontrolling interest** | $**13321** | $**13293** |

---

*Earnings Before Interest, Taxes, Depreciation and Amortization for Real Estate (EBITDAre) and Adjusted EBITDAre* 

The Company calculates EBITDA*re* in accordance with standards established by NAREIT and defines EBITDA*re* as net income or loss computed in accordance with GAAP plus depreciation and amortization, interest expense, gain or loss on the sale of investment properties, property impairment losses, and adjustments for unconsolidated partnerships and joint ventures to reflect EBITDAre on the same basis, as applicable. The Company defines Adjusted EBITDA*re* as EBITDA*re* plus loss on extinguishment of debt, non-cash stock compensation expense, non-cash intangible amortization related to above and below market leases, severance and transition related expense, expenses related to our reverse stock split, transaction expense, adjustments related to our investments in unconsolidated joint ventures, and other normalizing items. Management considers EBITDA*re* and Adjusted EBITDA*re* important measures because they provide additional information to allow management, investors, and our current and potential creditors to evaluate and compare our core operating results and our ability to service debt.

A reconciliation of net income to EBITDA*re* and Adjusted EBITDA*re* for the three months ended March 31, 2026 and 2025 is as follows:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,**  | **Three Months Ended March 31,**  |
|  | **2026** | **2025** |
|  | (unaudited and in thousands) | (unaudited and in thousands) |
| **Net income**  | $**1654** | $**3737** |
| Interest expense | 7233 | 7167 |
| Depreciation and amortization expense | 14827 | 13827 |
| Unconsolidated joint venture EBITDAre adjustments (<sup>1)</sup> | 111 | 85 |
| Gain on sale of investment properties |  | (1358) |
| &nbsp;&nbsp;**EBITDA*re*** | $**23825** | $**23458** |
| Stock-based compensation expense | 1229 | 151 |
| Amortization of above market leases, net | 146 | 452 |
| Severance and transition related expense |  | 104 |
| Interest rate swap mark-to-market at unconsolidated joint ventures | (19) | 35 |
| &nbsp;&nbsp;**Adjusted EBITDA*re*** | $**25181** | $**24200** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(1) Includes joint venture interest, depreciation and amortization, and gain on sale of investment properties, if applicable, included in unconsolidated joint ventures net income or loss.

*Net Operating Income (NOI), Cash NOI, and Same-Property Cash NOI*

The Company considers net operating income ("NOI") to be an appropriate supplemental measure to net income because it helps both investors and management understand the core operations of our properties. We define NOI as total net (loss) income, plus depreciation and amortization expenses, general and administrative expenses, transaction expenses, impairments, (gain) loss on sale of investment properties, interest expense, and other non-operating items. Cash NOI and Same-Property Cash NOI are key performance indicators. Management considers these to be supplemental measures that allows investors, analysts and Company management to measure unlevered property-level cash operating results. The Company defines Cash NOI as NOI excluding non-cash items such as above and below market lease intangibles and straight-line rent. Cash NOI is historical and not necessarily indicative of future results. Same-Property Cash NOI compares Cash NOI for stabilized properties. Stabilized properties are properties that have been included in operations for the duration of the year-over-year comparison period presented. Accordingly, stabilized properties exclude properties that were recently acquired or disposed of, properties classified as held for sale, properties undergoing redevelopment, and newly redeveloped or developed properties. Same-Property Cash NOI also excludes lease terminations fees and joint ventures and other income in order to remove non-recurring items and joint venture-related income from our NOI.

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
|  | (unaudited and in thousands) | (unaudited and in thousands) |
| **Net income** | $**1654** | $**3737** |
| General and administrative | 5089 | 3620 |
| Depreciation and amortization expense | 14827 | 13827 |
| Interest expense | 7233 | 7167 |
| Gain on sale of investment properties |  | (1358) |
| Proportionate share of unconsolidated joint venture adjustments | 92 | 120 |
| &nbsp;&nbsp;**NOI** | $**28895** | $**27113** |
| Amortization of above market leases, net | 146 | 452 |
| Straight line deferred rental revenue | (204) | (57) |
| Proportionate share of unconsolidated joint venture adjustments | (2) | (5) |
| &nbsp;&nbsp;**Cash NOI** | $**28835** | $**27503** |
| Assets not held for all periods | (1313) | (848) |
| Joint ventures and other income | (122) | (98) |
| &nbsp;&nbsp;**Same-Property Cash NOI** | $**27400** | $**26557** |

---

**Liquidity and Capital Resources**

***General***

Our short-term (up to 12 months) liquidity requirements include:

● Interest expense and scheduled principal payments on outstanding indebtedness;

● General and administrative expenses;

● Property operating expenses;

● Property acquisitions;

● Distributions on our common and preferred stock and OP Units and LTIP Units;

● Increased capital requirements for our joint ventures;

● Repurchases of our common stock; and

● Capital and tenant improvements and leasing costs.

In 2026, we are contractually obligated to pay, or have capital commitments for, principal and interest payments on our outstanding debt and ground and operating lease expenses. In addition, if we decide to redeem our Series A preferred stock in full, we would have to pay the liquidation preference of $77.6 million plus accrued dividends, fees and expenses.

Our long-term (beyond 12 months) liquidity requirements consist primarily of funds necessary to pay for acquisitions, capital and tenant improvements at our properties, scheduled debt maturities, general and administrative expenses, operating expenses, common stock repurchases, and distributions. Beyond 2026, we are contractually obligated to pay, or have capital commitments for, principal and interest payments on our outstanding debt and ground and operating lease expenses.

We expect to satisfy our short and long-term liquidity needs through various internal and external sources, including cash flow from operations, debt financing, sales of additional equity securities, the issuance of OP Units in connection with acquisitions of additional properties, proceeds from select property dispositions and recapitalization transactions.

***Sources of Liquidity***

Our primary internal sources of liquidity include cash flow from operations and proceeds from select property dispositions and recapitalization transactions. Our primary external sources of liquidity include net proceeds received from equity issuances, including the issuance of OP Units in connection with acquisitions of additional properties, and debt financing, including borrowings under our Credit Facility, secured term loans and Senior Note Facility.

***ATM Program***

In January 2024, the Company and the Operating Partnership implemented a $300 million "at-the-market" equity offering program, pursuant to which we may offer and sell (including through forward sales), from time to time, shares of our common stock (the "2024 ATM Program"). No shares were sold under the 2024 ATM Program during the three months ended March 31, 2026 or from April 1, 2026 through May 5, 2026.

In February 2026, the Company and the Operating Partnership implemented a $75 million "at-the-market" equity offering program, pursuant to which the Company may offer and sell (including through forward sales), from time-to-time, shares of its 8.00% Series B Cumulative Redeemable Preferred Stock (the "2026 Series B Preferred ATM Program"). No shares were sold under the 2026 Series B Preferred ATM Program during the three months ended March 31, 2026 or from April 1, 2026 through May 5, 2026.

***Debt Financing***

*Credit Facility.* Our Credit Facility consists of (i) the $350 million Term Loan A Tranches, (ii) the $150 million Term Loan B, and (iii) the $400 million Revolver. The Credit Facility also contains a $500 million accordion feature. As of May 5, 2026, we had unutilized borrowing capacity under the Credit Facility of $220.5 million.

The Credit Facility is an unsecured facility with a maturity of (i) October 2029 for the Revolver (subject to two, six-month extension options), (ii) October 2029, October 2030, and April 2031 for the Term Loan A Tranches, and (iii) February 2028 for Term Loan B. Interest rates on amounts outstanding under the Credit Facility equal SOFR plus a borrowing spread based on the current pricing grid in the Credit Facility.

As of March 31, 2026, we had 16 interest rate swaps (including forward-starting interest rate swaps) that are used to manage our interest rate risk. Five of our interest rate swaps related to Term Loan A with a combined notional value of $350 million that fixed the SOFR component on Term Loan A through April 2026 at 1.36%. Seven of our interest rate swaps are forward-starting swaps that fix the SOFR component of the Term Loan A Tranches at rates between 3.24% to 3.32% and have maturities in October 2029, October 2030, and April 2031. The remaining four of our interest rate swaps relate to our Term Loan B with a combined notional value of $150 million that fix the SOFR component on Term Loan B through January 2028 at 2.54%.

We are subject to a number of financial covenants under the Credit Facility, including, among other things, the following as of the end of each fiscal quarter, (i) a maximum consolidated unsecured leverage ratio of less than 60%, (ii) a maximum consolidated secured leverage ratio of less than 30%, (iii) a maximum consolidated secured recourse leverage ratio of less than 10%, (iv) a minimum fixed charge coverage ratio of 1.50:1.00, (v) a minimum unsecured interest coverage ratio of 1.50:1.00, (vi) a maximum consolidated leverage ratio of less than 60%, (vii) a maximum cash investment in joint ventures of 10% of total asset value and (viii) a minimum net worth of $595.6 million plus 75% of all net proceeds raised through equity offerings subsequent to June 30, 2025. As of March 31, 2026, management believed it complied with all of the financial and non-financial covenants contained in the Credit Facility.

*Total Fixed Debt*. Our fixed debt totaled $501.1 million on a gross basis at March 31, 2026, with a weighted average interest rate of 3.06% based on our interest rate swaps and at current leverage. The weighted average maturity of our fixed debt was 3.7 years at March 31, 2026.

*Other Fixed Debt.* We have $1.1 million in gross notes payable as of March 31, 2026. This debt is comprised of one instrument.

***Senior Note Facility***

On March 2, 2026, the Company entered into a Master Note and Guaranty Agreement (the "Senior Note Agreement") with NYL Investors LLC and certain of its affiliates (collectively, the "Purchasers"). The Agreement establishes an uncommitted senior unsecured note facility pursuant to which the Company may issue senior unsecured promissory notes ("Notes") from time to time in one or more series to the Purchasers in an aggregate principal amount of up to $150.0 million. The Senior Note Agreement does not obligate the Purchasers to purchase any Notes, and each issuance is subject to the Purchasers' discretion and satisfaction of customary conditions. Notes may be issued under the Senior Note Agreement during a period ending on the earliest of (i) the third anniversary of the effective date of the Senior Note Agreement, (ii) termination of the facility by either party upon written notice, (iii) termination following certain events of default, or (iv) acceleration of the Notes and termination of the facility. Notes issued under the Agreement may have maturities of up to ten years and will bear interest at rates determined at the time of issuance based on spreads over U.S. Treasury securities. As of March 31, 2026, no Notes had been issued or were outstanding under the Senior Note Agreement.

***Debt Activity***

During the three months ended March 31, 2026, we borrowed $17.1 million under the Credit Facility and repaid $8.3 million, for a net amount borrowed of $8.8 million. During the three months ended March 31, 2025, we borrowed $44.0 million under the Credit Facility and repaid $13.5 million, for a net amount borrowed of $30.5 million. As of March 31, 2026, the net outstanding Credit Facility balance was $662.3 million and as of May 5, 2026, we had unutilized borrowing capacity under the revolver component of the Credit Facility (the "Revolver") of $220.5 million.

***Common Stock Repurchase Program***

In August 2025, the Board approved a $50 million common stock repurchase program (the "Stock Repurchase Program"). Under the Stock Repurchase Program, we may purchase up to $50 million of our outstanding shares of common stock from time to time in the open market, including through block purchases, through privately negotiated transactions or pursuant to any Rule 10b5-1 trading plan, in accordance with applicable securities laws. The specific timing, price and size of purchases will depend on prevailing stock prices, general economic and market conditions and other considerations. The Stock Repurchase Program does not obligate us to repurchase any dollar amount or number of shares of our common stock and may be suspended or discontinued at any time. No shares were repurchased during the three months ended March 31, 2026 or from April 1, 2026 through May 5, 2026.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

Market risk includes risks that arise from changes in interest rates, foreign currency exchange rates, commodity prices, equity prices and other market changes that affect market sensitive instruments. In pursuing our business and investment objectives, we expect that the primary market risk to which we will be exposed is interest rate risk.

We may be exposed to the effects of interest rate changes primarily as a result of debt used to acquire healthcare facilities, including borrowings under the Credit Facility. The analysis below presents the sensitivity of the value of our variable rate financial obligations to selected changes in market interest rates. The range of changes chosen reflects our view of changes which are reasonably possible over a one-year period.

As of March 31, 2026, we had $172.0 million of unhedged borrowings outstanding under the Revolver (before the netting of unamortized debt issuance costs) that bears interest at a variable rate. See "Management's Discussion and Analysis of Financial Condition and Results of Operation—Liquidity and Capital Resources," for a detailed discussion of our Credit Facility. On March 31, 2026, SOFR on our outstanding floating-rate borrowings was 3.67%. Assuming no increase in the amount of our variable interest rate debt, if SOFR increased 100 basis points, our cash flow would decrease by approximately $1.7 million annually. Assuming no increase in the amount of our variable rate debt, if SOFR were reduced 100 basis points, our cash flow would increase by approximately $1.7 million annually.

Our interest rate risk management objectives are to limit the impact of interest rate changes on earnings and cash flows and to lower overall borrowing costs. To achieve our objectives, we may borrow at fixed rates or floating rates. See "*Management's Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Sources of Liquidity—Debt Financing*," for a description of our interest rate swaps.

We may enter into additional derivative financial instruments, including interest rate swaps and caps, in order to mitigate our interest rate risk on our future borrowings. We will not enter into derivative transactions for speculative purposes.

In addition to changes in interest rates, the value of our investments is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants/operators and borrowers, which may affect our ability to refinance our debt if necessary.

**Item 4. Controls and Procedures.** 

**Evaluation of Disclosure Controls and Procedures**

The Company's management, including its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this report. Based on such evaluation, the Company's Chief Executive Officer and Chief Financial Officer concluded that as of March 31, 2026, the Company's disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information it is required to disclose in reports that it files or submits under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

**Changes in Internal Control over Financial Reporting**

No changes were made to our internal control over financial reporting during our most recently completed fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

**Limitations on Effectiveness of Controls and Procedures**

In designing and evaluating the disclosure controls and procedures and the Company's internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and the Company's internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

**PART II OTHER INFORMATION**

**Item 1. Legal Proceedings**

We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on our financial condition or results of operations. From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. There can be no assurance that these matters that arise in the future, individually or in the aggregate, will not have a material adverse effect on our financial condition or results of operations in any future period.

**Item 1A. Risk Factors**

Information on risk factors can be found in Part I, Item 1A (Risk Factors) of our 2025 Annual Report. Except as set forth below, there have been no material changes from the risk factors previously disclosed in our 2025 Annual Report. Some statements in this Quarterly Report on Form 10-Q constitute forward-looking statements. Please refer to Part I, Item 2 of this Quarterly Report on Form 10-Q entitled "Special Note Regarding Forward-Looking Statements."

***If we acquire the Riviera and the Landing, we plan to establish a new SHOP segment. This SHOP segment may expose us to various operational risks, liabilities and claims that could adversely affect our ability to generate revenues or increase our costs and could adversely affect our business, financial condition and results of operations.***

Under the REIT tax rules, the senior housing communities in our potential SHOP segment that are "qualified healthcare properties" generally must be operated and managed for us by third-party managers and we have limited rights to direct or influence the business or operations of those communities. We expect that both our qualified and non-qualified healthcare properties in our SHOP segment will be managed or sub-managed by third-party managers. However, in each case, we will nonetheless participate directly in the financial performance of the communities' operations and will be ultimately responsible for all operational risks and other liabilities of such properties, other than those arising out of certain actions by our managers, such as gross negligence, fraud or willful misconduct. These risks include, and our financial performance will be impacted by, among other things, fluctuations in occupancy levels, the inability to charge desirable resident fees (including anticipated increases in those fees), increases in the cost of food, supplies, energy, labor (as a result of labor shortages, unionization, inflation or otherwise) or other services, rent control regulations, national and regional economic conditions, the imposition of new or increased taxes, capital expenditure requirements, changes in management or equity, accounting misstatements, professional and general liability claims, litigation and regulatory actions and the availability and cost of insurance. Additionally, new or smaller third-party managers may have less experience in managing these senior housing communities and may require more oversight or attention. Any one or a combination of these factors could impact the performance of our potential SHOP segment, which could adversely affect our business, financial condition and results of operations.

We generally hold the applicable healthcare license and enroll in applicable government healthcare programs on behalf of the properties in our SHOP segment, which subjects us to potential liability under various healthcare laws and regulations.

***Our inability to renew our management agreements with our potential SHOP managers and sub-managers on as favorable terms or at all, and our inability when necessary, to effectively and efficiently transition a SHOP community to a new manager or sub-manager, may have an adverse effect on our business, financial condition and results of operations***.

If we establish a SHOP segment, we will be party to management agreements with our SHOP managers and sub-managers. While our management and sub-management agreements may be renewed, either pursuant to pre-negotiated renewal rights or through negotiation, there can be no assurance that our managers or sub-managers will renew with us. Even if a manager or sub-manager renews its agreement with us, we cannot assure you that the renewals will be on favorable terms. This risk may be exacerbated if market conditions at the time of the renewal are not as favorable as they were at the time the agreement was initially entered into or if the manager or sub-manager is subject to financial or operational difficulties.

Our management and sub-management agreements will provide us and our managers and sub-managers with termination rights in certain circumstances. If our management or sub-management agreements are not renewed or are otherwise terminated, we may attempt to transition those properties to one or more managers or sub-managers or reposition those properties for an alternative use. We may not be successful in identifying suitable replacements or entering into management or sub-management agreements or other arrangements with new managers or sub-managers on a timely basis or on terms as favorable to us as our current management or sub-management agreements, if at all.

During transition periods to new managers or sub-managers or in connection with repositioning the property, the attention of existing managers or sub-managers may be diverted from the performance of the properties, which could cause the financial and operational performance at those properties to decline and could increase exposure to operational and compliance risks. We may be required to fund certain expenses and obligations (such as real estate taxes, debt costs and maintenance expenses) or provide certain indemnities to preserve the value of, and avoid the imposition of liens on, our properties while they are being repositioned. Our ability to transition our properties to a suitable replacement manager or sub-manager or reposition our properties could be significantly delayed or limited by state licensing, receivership, certificates of need, Medicaid change-of-ownership rules or other legal and regulatory requirements or restrictions. The inability to replace a manager or sub-manager on a timely or successful basis could have an adverse effect on our business, financial condition and results of operations.

***If we establish a SHOP segment, significant legal or regulatory proceedings could subject us or our managers or sub-managers to increased operating costs and substantial uninsured liabilities, which could adversely affect our or their liquidity, financial condition and results of operations.***

If we establish a SHOP segment, from time to time, we or our managers or sub-managers may be subject to lawsuits, investigations, claims and other legal or regulatory proceedings arising out of our or their alleged actions or inactions. Also, in certain circumstances, regardless of whether we are a named party in a lawsuit, investigation, claim or other legal or regulatory proceeding, we may be contractually obligated to indemnify, defend and hold harmless our managers, sub-managers and other third parties against, or may otherwise be responsible for such actions, proceedings or claims. These claims may include, among other things, professional liability and general liability claims, commercial liability claims, unfair business practices claims, class action claims, employment-related claims, as well as regulatory proceedings, including proceedings related to our SHOP segment, where we are typically the holder of the applicable healthcare license. In addition, some of our properties may be in states in which the litigation environment may pose a significant business risk to us.

In our potential operating assets, we will be generally responsible for all liabilities of the properties, including any lawsuits, investigations, claims and other legal or regulatory proceedings, other than those arising out of certain limited actions by our managers or sub-managers, such as those caused by gross negligence, fraud or willful misconduct. As a result, we will have exposure to, among other things, professional and general liability claims, employment-related claims and the associated litigation and other costs related to defending and resolving such claims, some of which may be uninsured, either as a result of insufficient coverage or unavailability of coverage at a reasonable price.

If one of our managers or sub-managers fails to comply with applicable law or regulation, we may be held responsible, which could subject us to civil, criminal and administrative penalties, including the loss or suspension of accreditation, licenses or certificates of need with respect to a single community or more broadly; suspension of or nonpayment for new admissions; denial of reimbursement; fines; suspension, decertification, or exclusion from federal, state or foreign healthcare programs; or facility closure. In addition, we cannot assure you that any contractual obligations to indemnify, defend and hold us harmless from such liabilities will be satisfied by third parties, or that any amounts held in escrow for such purpose will be sufficient.

An unfavorable resolution of any such lawsuit, investigation, claim or other legal or regulatory proceeding could materially and adversely affect our or our managers' or sub-managers' liquidity, financial condition and results of operations, and may not be protected by sufficient or any insurance coverage. Even with a favorable resolution of litigation or a proceeding, the effect of litigation and other potential litigation and proceedings may divert the attention of management and materially increase operating costs we or our managers or sub-managers incur. Negative publicity with respect to any lawsuits, claims or other legal or regulatory proceedings may also negatively impact their or our or the affected properties' reputation.

Our business may be subject to lawsuits or other legal or regulatory proceedings such as professional or general liability litigation alleging wrongful death and negligence claims, some of which may result in large damage awards and not be indemnified or subject to sufficient insurance coverage, may require our support as a result of our indemnification agreements or may result in restrictions in the operations of our or our managers' or sub-managers' business.

***If we establish a SHOP segment, events that adversely affect the ability of seniors and their families to afford resident fees at our seniors housing facilities could cause our occupancy rates, revenues and results of operations to decline.***

Costs to seniors associated with independent, assisted living and memory care services are generally not reimbursable under government reimbursement programs such as Medicare and Medicaid. Only seniors with sufficient income or assets or other resources will be able to afford to pay the monthly resident fees, and a weak economy, depressed housing market or changes in demographics could adversely affect their continued ability to do so. If our managers or sub-managers are unable to retain and attract seniors with sufficient income, assets or other resources required to pay the fees associated with independent and assisted living services, our

occupancy rates and revenues could decline, which could, in turn, materially adversely affect our business, results of operations and financial condition.

***If we establish a SHOP segment, our ability to lease certain of our potential seniors housing facilities to our TRS lessee will be limited by the ability of those seniors housing facilities to qualify as "qualified healthcare properties."***

If we establish a SHOP segment, we may lease certain of our seniors housing facilities to our TRS lessee, which would contract with managers to manage the healthcare operations at those facilities. Our ability to use this TRS lessee structure may be limited by the ability of those seniors housing facilities to qualify as "qualified healthcare properties" and the ability of the managers who our TRS lessee engages to manage the "qualified healthcare properties" to qualify as "eligible independent contractors."

A "qualified healthcare property" includes any real property and any personal property that is, or is necessary or incidental to the use of, a hospital, nursing facility, assisted living facility, congregate care facility, qualified continuing care facility or other licensed facility which extends medical or nursing or ancillary services to patients and which is operated by a provider of such services which is eligible for participation in the Medicare program with respect to such facilities. Some of our properties may not be treated as "qualified healthcare properties." To the extent a property does not constitute a "qualified healthcare property," we will be unable to use the TRS lessee structure with respect to that property.

***If we establish a SHOP segment and our TRS lessee failed to qualify as a TRS or the facility managers engaged by our TRS lessee do not qualify as "eligible independent contractors," we could fail to qualify as a REIT and could be subject to higher taxes.***

Rent paid by a lessee that is a "related party tenant" of ours will not be qualifying income for purposes of the two gross income tests applicable to REITs. If we establish a SHOP segment, we may lease certain of our potential seniors housing facilities that qualify as "qualified healthcare properties" to our TRS lessee. So long as our TRS lessee qualifies as a TRS, it will not be treated as a "related party tenant" with respect to our "qualified healthcare properties" that are managed by an independent facility manager that qualifies as an "eligible independent contractor." We expect that our TRS lessee will qualify to be treated as a TRS for U.S. federal income tax purposes, but there can be no assurance that the IRS will not challenge the status of our TRS lessee for U.S. federal income tax purposes or that a court would not sustain such a challenge. If the IRS were successful in disqualifying our TRS lessee from treatment as a TRS, we could fail to meet the asset tests applicable to REITs and we could fail to satisfy the gross income tests. If we failed to meet either the asset or gross income tests, we could lose our REIT qualification for U.S. federal income tax purposes unless we qualified for application of statutory savings provisions.

Additionally, if the managers engaged by our TRS lessee do not qualify as "eligible independent contractors," we could fail to qualify as a REIT. Each of the managers that enter into a management contract with our TRS lessee must qualify as an "eligible independent contractor" under the REIT rules in order for the rent paid to us by our TRS lessee to be qualifying income for purposes of the REIT gross income tests. Among other requirements, in order to qualify as an eligible independent contractor, a manager must not own, directly or indirectly, more than 35% of our outstanding stock and no person or group of persons can own more than 35% of our outstanding stock and the ownership interests of the manager, taking into account certain ownership attribution rules. The ownership attribution rules that apply for purposes of these 35% thresholds are complex. Although we intend to monitor ownership of our stock by our managers and their owners, there can be no assurance that these ownership levels will not be exceeded.

In addition, in order to qualify as an "eligible independent contractor," among other requirements, a manager (or a related person) must be actively engaged in the trade or business of operating "qualified healthcare properties" for persons who are not related to us or our TRS lessee. Consequently, if a manager (or a related person) with respect to a "qualified healthcare property" of ours does not operate sufficient "qualified healthcare properties" for third parties, the manager will not qualify as an "eligible independent contractor."

***If we establish a SHOP segment, the ability of our TRSs to manage certain of our potential independent living facilities will be dependent on such facilities not constituting "qualified healthcare properties."***

If we establish a SHOP segment, we plan to engage TRSs to manage certain of our independent living facilities. Our ability to utilize TRSs in such a role depends on those independent living facilities not constituting "qualified healthcare properties" within the meaning of the U.S. federal income tax rules applicable to REITs. While we believe that such independent living facilities are not "qualified healthcare properties," if the IRS challenged such belief and a court sustained such a challenge, our income from the properties could fail to qualify as rents from real property for purposes of the REIT gross income tests, and as a result we could fail to qualify as a REIT.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds** 

**Recent Sales of Unregistered Securities**

None.

**Issuer Purchases of Equity Securities**

None.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

**Item 6. Exhibits** 

**(a)** **Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 3.1 | [Articles of Restatement of Chiron Real Estate Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q as filed with the SEC on August 8, 2018).](https://www.sec.gov/Archives/edgar/data/1533615/000114420418042820/tv500173_ex3-1.htm) |
| 3.2 | [Articles of Amendment of Chiron Real Estate Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 19, 2025).](https://www.sec.gov/Archives/edgar/data/1533615/000110465925091732/tm2526504d1_ex3-1.htm) |
| 3.3 | [Articles Supplementary for Chiron Real Estate Inc. 8.00% Series B Cumulative Redeemable Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on November 18, 2025).](https://www.sec.gov/Archives/edgar/data/1533615/000110465925113664/tm2531522d1_ex3-1.htm) |
| 3.4 | [Articles of Amendment of Chiron Real Estate Inc. (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on February 25, 2026).](https://www.sec.gov/Archives/edgar/data/1533615/000110465926019760/tm267304d1_ex3-1.htm) |
| 3.5 | [Articles Supplementary, classifying and designating 3,000,000 additional shares of Series B Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K as filed with the SEC on March 13, 2026).](https://www.sec.gov/Archives/edgar/data/1533615/000110465926027195/tm268627d1_ex3-1.htm) |
| 3.6 | [Fifth Amended and Restated Bylaws of Chiron Real Estate Inc., effective as of February 23, 2026 (incorporated herein by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K as filed with the SEC on February 25, 2026).](https://www.sec.gov/Archives/edgar/data/1533615/000110465926019760/tm267304d1_ex3-2.htm) |
| 4.1 | [Specimen of Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-11/A as filed with the SEC on June 15, 2016).](https://www.sec.gov/Archives/edgar/data/1533615/000114420416108273/v442252_ex4-1.htm) |
| 4.2 | [Specimen of 7.50% Series A Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on September 14, 2017).](https://www.sec.gov/Archives/edgar/data/1533615/000114420417048049/v475155_ex4-1.htm) |
| 4.3 | [Specimen of 8.00% Series B Cumulative Redeemable Preferred Stock Certificate (incorporated herein by reference to Exhibit 4.1 to the Company's Current Report on Form 8-K as filed with the SEC on November 18, 2025).](https://www.sec.gov/Archives/edgar/data/1533615/000110465925113664/tm2531522d1_ex4-1.htm) |
| 10.1\* | [First Amendment to Third Amended and Restated Credit Facility Agreement, dated March 17, 2026, by and among Chiron Real Estate LP, Chiron Real Estate Inc., the certain Subsidiaries from time to time party thereto as Guarantors, and JPMorgan Chase Bank, N.A., as administrative agent, and the several banks, financial institutions and other entities from time-to-time party thereto as lenders.](xrn-20260331xex10d1.htm) |
| 10.2 | [Master Note and Guaranty Agreement, dated March 2, 2026, by and among Chiron Real Estate LP, Chiron Real Estate Inc. and NYL Investors LLC and certain of its affiliates (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on March 3, 2026).](https://www.sec.gov/Archives/edgar/data/1533615/000110465926022515/tm267766d1_ex10-1.htm) |
| 10.3 | [Sixth Amendment to Agreement of Limited Partnership of Chiron Real Estate LP, dated as of March 11, 2026 (incorporated herein by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K as filed with the SEC on March 13, 2026).](https://www.sec.gov/Archives/edgar/data/1533615/000110465926027195/tm268627d1_ex10-1.htm) |
| 31.1\* | [Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](xrn-20260331xex31d1.htm) |
| 31.2\* | [Certification of Principal Financial and Accounting Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](xrn-20260331xex31d2.htm) |
| 32.1\*\* | [Certification of Principal Executive Officer and Principal Financial and Accounting Officer, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](xrn-20260331xex32d1.htm) |

---

---

| | |
|:---|:---|
| 101.INS \* | Inline XBRL Instance Document |
| 101.SCH \* | Inline XBRL Taxonomy Schema |
| 101.CAL \* | Inline XBRL Taxonomy Calculation Linkbase |
| 101.DEF \* | Inline XBRL Taxonomy Definition Linkbase |
| 101.LAB \* | Inline XBRL Taxonomy Label Linkbase |
| 101.PRE \* | Inline XBRL Taxonomy Presentation Linkbase |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101) |

---

\* Filed herewith.

\*\* Furnished herewith. Such certification shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | **Chiron Real Estate Inc**. |
| Date: May 7, 2026 | By: | /s/ *Mark O. Decker, Jr.* |
|  |  | Mark O. Decker, Jr. |
|  |  | Chief Executive Officer (Principal Executive Officer) |
| Date: May 7, 2026 | By: | /s/ *Robert J. Kiernan* |
|  |  | Robert J. Kiernan |
|  |  | Chief Financial Officer (Principal Financial and Accounting Officer) |

---

## Exhibit 10.1

Exhibit 10.1

**AMENDMENT NO. 1 TO THIRD <br>AMENDED AND RESTATED CREDIT AGREEMENT**

This **AMENDMENT NO. 1 TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT**, dated as of March 17, 2026 (this "<u>Amendment</u> <u>No</u>. <u>1</u>"), is by and among Chiron Real Estate LP (f/k/a Global Medical REIT L.P.), a Delaware limited partnership (the "<u>Borrower</u>"), Chiron Real Estate Inc. (f/k/a Global Medical REIT Inc.), a Maryland corporation (the "<u>Parent</u>" or "<u>Chiron REIT</u>"), the certain Subsidiaries from time to time party to this Agreement as Guarantors, JPMORGAN CHASE BANK, N.A., as administrative agent for the Lenders (as defined below) (the "<u>Administrative Agent</u>"), and the Lenders party hereto. Reference is made to that certain Third Amended and Restated Credit Agreement, dated as of October 8, 2025 (the "<u>Original Credit Agreement</u>", and as amended, restated, amended and restated, supplemented or otherwise modified from time to time, including pursuant to this Amendment No. 1, the "<u>Credit Agreement</u>"), among the Borrower, Chiron REIT, the Subsidiary Guarantors party thereto, the several banks, financial institutions and other entities from time to time party thereto (collectively, the "<u>Lenders</u>"), and the Administrative Agent. Capitalized terms used herein without definition shall have the same meanings as set forth in the Credit Agreement.

**RECITALS**

**WHEREAS**, the Borrower has requested that the Administrative Agent and the Lenders make certain amendments to the Credit Agreement in order to permit senior housing assets, and the Administrative Agent and the Lenders are willing to make such amendments on the terms and conditions set forth herein;

**NOW, THEREFORE,** in consideration of the premises and the agreements, provisions and covenants herein contained, the parties hereto agree as follows:

**SECTION 1. AMENDMENT TO CREDIT Agreement.** As of the Amendment Effective Date (as defined in Section 4 hereof), the Original Credit Agreement is hereby amended as follows:

Section 1.01. <u>Amended Credit Agreement</u>. As of the Amendment Effective Date, the Credit Agreement (excluding the Exhibits and Schedules) is hereby amended as set forth on <u>Exhibit A</u> attached hereto such that all of the newly inserted bold, double-underlined text (indicated textually in the same manner as the following examples: <<u>double-underlined text</u>> and <<u>double-underlined text</u>>) and any formatting changes reflected therein shall be deemed to be inserted and reflected in the text of the Credit Agreement and all of the deleted stricken text (indicated textually in the same manner as the following examples: stricken text and stricken text) shall be deemed to be deleted from the text of the Credit Agreement.

**SECTION 2. REPRESENTATIONS AND WARRANTIES OF THE BORROWER**

In order to induce the Lenders and Administrative Agent to enter into this Amendment No. 1, each of the Borrower and each Guarantor represents and warrants to the Lenders and the Administrative Agent as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)It has the full right and legal authority to execute and deliver each of this Amendment No. 1 and the Credit Agreement as amended by Amendment No. 1 (collectively, the

------

"<u>Amendment Documents</u>") and to perform its obligations thereunder and under the Credit Agreement. The execution and delivery by it of the Amendment Documents and the performance of its obligations thereunder and under the Credit Agreement have been duly authorized by proper proceedings. The Amendment Documents to which it is party have been duly executed and delivered by it and the Amendment Documents and the Credit Agreement to which it is party constitute legal, valid and binding obligations of it enforceable against it in accordance with their terms, except as enforceability may be limited by bankruptcy, insolvency or similar laws affecting the enforcement of creditors' rights generally and general principles of equity (regardless of whether the application of such principles is considered in a proceeding in equity or at law).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)The Amendment Documents and the Credit Agreement do not, nor does the performance or observance by the Borrower or any Subsidiary of any of the matters and things herein or therein provided for, (a) contravene or constitute a default under any applicable Legal Requirement binding upon the Borrower or any Guarantor or any provision of the organizational documents (*e.g.*, charter, certificate or articles of incorporation and by-laws, certificate or articles of association and operating agreement, partnership agreement, or other similar organizational documents) of the Borrower or any Guarantor, (b) contravene or constitute a default under any covenant, indenture or agreement of the Borrower or any Guarantor or affecting any of their Property, in each case where such contravention or default, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect, or (c) result in the creation or imposition of any Lien on any Property of the Borrower or any Guarantor (other than in favor of the Administrative Agent for its benefit and the benefit of the Lenders and the L/C Issuer). No authorization, consent, license or exemption from, or filing or registration with, any Governmental Authority, nor any approval or consent of any other Person, is or will be necessary to the valid execution, delivery or performance by the Borrower or any Guarantor of any Amendment Document, except (a) those that have otherwise been obtained or made on or prior to the Amendment Effective Date and which remain in full force and effect on the Amendment Effective Date and (b) where the failure to obtain such authorizations, consents, licenses, exemptions or approvals, or make such filings or registrations, would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)The Borrower is duly organized, validly existing, and in good standing as a limited partnership under the laws of the State of Delaware. Chiron REIT is duly organized, validly existing, and in good standing as a corporation under the laws of the State of Maryland. Each Subsidiary Guarantor is duly organized, validly existing, and in good standing under the laws of the jurisdictions in which it is organized.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)Each of the representations and warranties made by the Borrower and each Guarantor in or pursuant to the Loan Documents are true and correct in all material respects (or, in the case of any representation and warranty that is qualified as to "materiality," "Material Adverse Effect" or similar language, true and correct (after giving effect to any qualification therein) in all respects) on and as of the Amendment Effective Date as if made on and as of such date except for representations and warranties expressly stated to relate to a specific earlier date, in which case such representations and warranties were true and correct in all material respects (or, in the case of any representation and warranty that is qualified as to "materiality," "Material

------

Adverse Effect" or similar language, true and correct (after giving effect to any qualification therein) in all respects) as of such earlier date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)Since December 31, 2025, there has been no change in the business, financial condition, operations, performance or properties of Chiron REIT, the Borrower and the Subsidiaries taken as a whole, which would reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)No Default or Event of Default has occurred and is continuing on the Amendment Effective Date after giving effect to this Amendment No. 1.

**SECTION 3. REAFFIRMATION OF GUARANTY; release of guarantors** 

**A**. Each of Chiron REIT and the undersigned Subsidiary Guarantors (other than the Released Guarantors, as defined below) has read this Amendment No. 1 and consents to the terms hereof and further hereby confirms and agrees that, notwithstanding the effectiveness of this Amendment No. 1, the obligations of Chiron REIT and such Subsidiary Guarantor under each of the Loan Documents to which Chiron REIT and such Subsidiary Guarantor is a party (including its guaranty obligations under Section 13 of the Credit Agreement) shall not be impaired and each of the Loan Documents to which Chiron REIT and such Subsidiary Guarantor is a party is, and shall continue to be, in full force and effect and is hereby confirmed and ratified in all respects, and shall extend to the Incremental Term Loans made hereunder.

Each of Chiron REIT, the Subsidiary Guarantors and the Borrower hereby acknowledges and agrees that each reference to the defined term "Obligations" under, and as defined in Section 13 of the Credit Agreement will be understood to refer to the "Obligations" under and as defined in the Credit Agreement.

**B**. Each Credit Party hereby fully, finally and irrevocably releases each of GMR Melbourne, LLC and GMR Memphis Exeter, LLC (collectively, the "<u>Released Guarantors</u>") from its obligations as a Guarantor pursuant to the Credit Agreement and from its obligations under its Guaranty.

**SECTION 4. CONDITIONS TO EFFECTIVENESS**

This Amendment No. 1 shall become effective as of the date hereof (the "<u>Amendment</u> <u>Effective Date</u>"), subject to the satisfaction (or waiver by the Administrative Agent and each Lender) of the following conditions precedent:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A.** the Borrower, Chiron REIT, each Subsidiary Guarantor, the Administrative Agent, and Lenders constituting the Required Lenders shall have indicated their consent to the matters covered by this Amendment No. 1 by the execution of the signature pages hereto and the delivery of such signature pages to the Administrative Agent; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B.** the Administrative Agent shall have received all reasonable, documented out-of-pocket costs and expenses incurred in connection with this Amendment No. 1 for which the Borrower is responsible pursuant to Section 12.15 of the Credit Agreement and for which invoices

------

have been presented at least one Business Day prior to the Amendment Effective Date (including the reasonable fees and expenses of legal counsel to the Administrative Agent for which the Borrower is responsible pursuant to Section 12.15 of the Credit Agreement).

**SECTION 5. MISCELLANEOUS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**A. Reference to and Effect on the Credit Agreement and the Other Loan Documents**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)On and after the effective date of this Amendment No. 1, each reference in the Credit Agreement to "this Agreement", "hereunder", "hereof", "herein" or words of like import referring to the Credit Agreement and each reference in the other Loan Documents to the "Credit Agreement", "thereunder", "thereof" or words of like import referring to the Credit Agreement shall mean and be a reference to the Credit Agreement as amended by this Amendment No. 1. This Amendment No. 1 shall be deemed to be a "Loan Document" under the Credit Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)Except as specifically amended by this Amendment No. 1, the Credit Agreement and the other Loan Documents shall remain in full force and effect and are hereby ratified and confirmed. The parties hereto do not intend this Amendment No. 1 or the transactions contemplated hereby to be, and this Amendment No. 1 and the transactions contemplated hereby shall not be construed to be, a novation of any of the obligations owing by the Borrower under or in connection with the Credit Agreement or any of the Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)The execution, delivery and performance of this Amendment No. 1 shall not, except as expressly provided herein, constitute a waiver of any provision of, or operate as a waiver of any right, power or remedy of the Administrative Agent or any Lender under the Credit Agreement or any of the other Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**B. Administrative Agent.** Each Credit Party hereby directs the Administrative Agent to execute this Amendment No. 1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**C. Headings**. Section and subsection headings in this Amendment No. 1 are included herein for convenience of reference only and shall not constitute a part of this Amendment No. 1 for any other purpose or be given any substantive effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**D. [Reserved]**.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**E. Counterparts; Effectiveness**. This Amendment No. 1 may be executed in any number of counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all signature pages are physically attached to the same document. Delivery of an executed counterpart of a signature page to this Amendment No. 1 that is an Electronic Signature transmitted by telecopy, emailed pdf. or any other electronic means that reproduces an image of an actual executed signature page in accordance with Section 12.9(b) of the Credit Agreement shall be effective as delivery of a manually executed counterpart of this Amendment No. 1.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**F. Governing Law; Jurisdictions; Immunities; Waiver of Jury Trial**. The provisions of Sections 12.18 and 12.23 of the Credit Agreement shall apply to this Amendment No. 1 and are hereby incorporated by reference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**G. Successors**. The provisions of this Amendment No. 1 shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns.

**[Signature Pages Follow]**

------

**IN WITNESS WHEREOF**, the parties hereto have caused this Amendment No. 1 to be duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above.

BORROWER:

**CHIRON REAL ESTATE LP**

**By:** **CHIRON REAL ESTATE GP LLC,**

a Delaware limited liability company,

its General Partner

**By:** **CHIRON REAL ESTATE INC.,**

a Maryland Corporation,

its Sole Member

By:<u>/s/ Robert Kiernan</u> 

Name:Robert Kiernan

Title:Treasurer and Chief Financial Officer

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**GUARANTORS**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**CHIRON REAL ESTATE Inc.** | &nbsp;&nbsp;**CHIRON REAL ESTATE Inc.** |
| &nbsp;&nbsp;By: | &nbsp;&nbsp;<u>/s/ Robert Kiernan</u>  |
| &nbsp;&nbsp;Name: | &nbsp;&nbsp;Robert Kiernan |
| &nbsp;&nbsp;Title: | &nbsp;&nbsp;Treasurer and Chief Financial Officer |

---

&nbsp;&nbsp;**GMR Albertville, LLC**<br>**GMR Altoona, LLC**<br>**GMR Amarillo, LLC**<br>**GMR Asheville, LLC**<br>**GMR Athens-200, LLC**<br>**GMR Athens-600, LLC**<br>**GMR Austin, LLC**<br>**GMR Bannockburn, LLC**<br>**GMR Bastrop, LLC**<br>**GMR Beaumont, LLC**<br>**GMR Belpre, LLC**<br>**GMR Bountiful, LLC**<br>**GMR Bradenton 2101 61**<sup>st</sup> **Street, LLC**<br>**GMR Bradenton 2203 61**<sup>st</sup> **Street, LLC**<br>**GMR Bradenton 53**<sup>rd</sup> **Avenue, LLC**<br>**GMR Bradenton Pointe West, LLC**<br>**GMR Brockport, LLC**<br>**GMR Caledonia, LLC**<br>**GMR Canandaigua, LLC**<br>**GMR Cape Coral Viscaya 1255, LLC**<br>**GMR Cape Coral Viscaya 1261, LLC**<br>**GMR Cape Coral Viscaya 1265, LLC**<br>**GMR Cape Coral, LLC**<br>**GMR Cape Coral Southeast, LLC**<br>**GMR Cape Girardeau, LLC**<br>**GMR Centerville, LLC**<br>**GMR Cerritos, LLC**<br>**GMR Chandler Dobson, LLC**<br>**GMR Chandler Pecos I, LLC**<br>**GMR Chandler Pecos II, LLC**<br>**GMR Chandler Val Vista I, LLC**<br>**GMR Cincinnati Beechmont, LLC**<br>**GMR Clermont, LLC**<br>**GMR Clinton Township, LLC**<br>**GMR Clinton, LLC**<br>**GMR Clive, LLC**<br>**GMR Conway, LLC**<br>

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

&nbsp;&nbsp;**GMR Corona, LLC**<br>**GMR Dallas North Central, LLC**<br>**GMR Danville, LLC**<br>**GMR Decatur, LLC**<br>**GMR Des Moines EN, LLC**<br>**GMR Des Moines West, LLC**<br>**GMR Dumfries, LLC**<br>**GMR East Dallas Hospital, LLC**<br>**GMR East Dallas Land, LLC**<br>**GMR East Grand Forks, LLC**<br>**GMR East Orange, LLC**<br>**GMR East Venice, LLC**<br>**GMR El Paso, LLC**<br>**GMR Fairbanks, LLC**<br>**GMR Fairfax Hamaker, LLC**<br>**GMR Fairfax, LLC**<br>**GMR Flower Mound, LLC**<br>**GMR Forsyth 241 Weaver, LLC**<br>**GMR Forsyth 389 Weaver, LLC**<br>**GMR Fort Myers Camelot, LLC**<br>**GMR Fort Myers Park Royal, LLC**<br>**GMR Fort Worth Overton Ridge, LLC**<br>**GMR Frankfort, LLC**<br>**GMR Fremont, LLC**<br>**GMR Gainesville Sherwood, LLC**<br>**GMR Gainesville, LLC**<br>**GMR Gilbert, LLC**<br>**GMR Glenview, LLC**<br>**GMR Grand Rapids Beltline, LLC**<br>**GMR Grand Rapids Main, LLC**<br>**GMR Grand Rapids Walker, LLC**<br>**GMR Grand Rapids Wilson, LLC**<br>**GMR Greenwood Emerson, LLC**<br>**GMR Greenwood, LLC**<br>**GMR Hermitage Garden Way, LLC**<br>**GMR Hialeah, LLC**<br>**GMR Hudson, LLC**<br>**GMR Jackson, LLC**<br>**GMR Jacksonville Riverside LLC**<br>**GMR Lake Geneva, LLC**<br>**GMR Lancaster, LLC**<br>**GMR Lansing Jolly 3390, LLC**<br>**GMR Lansing Jolly 3400, LLC**<br>**GMR Lansing Patient, LLC**<br>**GMR Las Cruces, LLC**<br>**GMR Las Vegas Pecos, LLC**<br>

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

&nbsp;&nbsp;**GMR Las Vegas Warm Springs, LLC**<br>**GMR Las Vegas, LLC**<br>**GMR Lee's Summit Northeast, LLC**<br>**GMR Lee's Summit, LLC**<br>**GMR Lemoyne, LLC**<br>**GMR Lewisburg, LLC**<br>**GMR Little Rock, LLC**<br>**GMR Livonia, LLC**<br>**GMR London, LLC**<br>**GMR Lubbock, LLC**<br>**GMR McAllen, LLC**<br>**GMR Mechanicsburg, LLC**<br>**GMR Melbourne Pine, LLC**<br>**GMR Melbourne, LLC**<br>**GMR Memphis Exeter, LLC**<br>**GMR Memphis, LLC**<br>**GMR Mentor, LLC**<br>**GMR Mesa, LLC**<br>**GMR Minot, LLC**<br>**GMR Moline, LLC**<br>**GMR Morgantown, LLC**<br>**GMR Munster, LLC**<br>**GMR Oklahoma Northwest, LLC**<br>**GMR Omaha, LLC**<br>**GMR Orlando, LLC**<br>**GMR Paris, LLC**<br>**GMR Pensacola Davis, LLC**<br>**GMR Pensacola Grande, LLC**<br>**GMR Pensacola Market, LLC**<br>**GMR Pittsburgh, LLC**<br>**GMR Plano, LLC**<br>**GMR Plymouth, LLC**<br>**GMR Port St. Lucie, LLC**<br>**GMR Reading, LLC**<br>**GMR Redding Butte, LLC**<br>**GMR Redding Churn Creek, LLC**<br>**GMR Rocky Point, LLC**<br>**GMR Rosedale 5233, LLC**<br>**GMR Rosedale 5235, LLC**<br>**GMR Ruskin, LLC**<br>**GMR Russellville, LLC**<br>**GMR Saint George, LLC**<br>**GMR San Marcos, LLC**<br>**GMR Sandusky, LLC**<br>**GMR Sarasota Clark, LLC**<br>**GMR Sarasota, LLC**<br>

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**GMR Sheboygan, LLC**<br>**GMR Sherman, LLC**<br>**GMR Silvis, LLC**<br>**GMR SLIPPERY ROCK, LLC**<br>**GMR SOMERSET, LLC**<br>**GMR Southern IL Shiloh 1191, LLC**<br>**GMR Southern IL Shiloh 1197, LLC**<br>**GMR Southern IL Carbondale, LLC**<br>**GMR Southern IL, LLC**<br>**GMR Spartanburg, LLC**<br>**GMR Spring Hill County Line, LLC**<br>**GMR Spring Hill Medical Center, LLC**<br>**GMR Surprise, LLC**<br>**GMR Syracuse, LLC**<br>**GMR Tallahassee, LLC**<br>**GMR Toledo, LLC**<br>**GMR Tucson Carondelet, LLC**<br>**GMR Tucson Silverbell, LLC**<br>**GMR Venice, LLC**<br>**GMR Vernon Keynote, LLC**<br>**GMR Vernon, LLC**<br>**GMR Watertown, LLC**<br>**GMR West Allis, LLC**<br>**GMR West El Paso, LLC**<br>**GMR Westland Central City, LLC**<br>**GMR Westland, LLC**<br>**GMR Winston-Salem, LLC**<br>**GMR Wyomissing, LLC**<br>**GMR Yuma 20, LLC**<br>**GMR Yuma 25, LLC**<br>**GMR Zachary, LLC** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**GMR Sheboygan, LLC**<br>**GMR Sherman, LLC**<br>**GMR Silvis, LLC**<br>**GMR SLIPPERY ROCK, LLC**<br>**GMR SOMERSET, LLC**<br>**GMR Southern IL Shiloh 1191, LLC**<br>**GMR Southern IL Shiloh 1197, LLC**<br>**GMR Southern IL Carbondale, LLC**<br>**GMR Southern IL, LLC**<br>**GMR Spartanburg, LLC**<br>**GMR Spring Hill County Line, LLC**<br>**GMR Spring Hill Medical Center, LLC**<br>**GMR Surprise, LLC**<br>**GMR Syracuse, LLC**<br>**GMR Tallahassee, LLC**<br>**GMR Toledo, LLC**<br>**GMR Tucson Carondelet, LLC**<br>**GMR Tucson Silverbell, LLC**<br>**GMR Venice, LLC**<br>**GMR Vernon Keynote, LLC**<br>**GMR Vernon, LLC**<br>**GMR Watertown, LLC**<br>**GMR West Allis, LLC**<br>**GMR West El Paso, LLC**<br>**GMR Westland Central City, LLC**<br>**GMR Westland, LLC**<br>**GMR Winston-Salem, LLC**<br>**GMR Wyomissing, LLC**<br>**GMR Yuma 20, LLC**<br>**GMR Yuma 25, LLC**<br>**GMR Zachary, LLC** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**GMR Sheboygan, LLC**<br>**GMR Sherman, LLC**<br>**GMR Silvis, LLC**<br>**GMR SLIPPERY ROCK, LLC**<br>**GMR SOMERSET, LLC**<br>**GMR Southern IL Shiloh 1191, LLC**<br>**GMR Southern IL Shiloh 1197, LLC**<br>**GMR Southern IL Carbondale, LLC**<br>**GMR Southern IL, LLC**<br>**GMR Spartanburg, LLC**<br>**GMR Spring Hill County Line, LLC**<br>**GMR Spring Hill Medical Center, LLC**<br>**GMR Surprise, LLC**<br>**GMR Syracuse, LLC**<br>**GMR Tallahassee, LLC**<br>**GMR Toledo, LLC**<br>**GMR Tucson Carondelet, LLC**<br>**GMR Tucson Silverbell, LLC**<br>**GMR Venice, LLC**<br>**GMR Vernon Keynote, LLC**<br>**GMR Vernon, LLC**<br>**GMR Watertown, LLC**<br>**GMR West Allis, LLC**<br>**GMR West El Paso, LLC**<br>**GMR Westland Central City, LLC**<br>**GMR Westland, LLC**<br>**GMR Winston-Salem, LLC**<br>**GMR Wyomissing, LLC**<br>**GMR Yuma 20, LLC**<br>**GMR Yuma 25, LLC**<br>**GMR Zachary, LLC** |
| &nbsp;&nbsp;**By:**  | &nbsp;&nbsp;**CHIRON REAL ESTATE LP,** <br>its Sole Member  | &nbsp;&nbsp;**CHIRON REAL ESTATE LP,** <br>its Sole Member  |
|  | &nbsp;&nbsp;**CHIRON REAL ESTATE GP LLC,**<br>its General Partner | &nbsp;&nbsp;**CHIRON REAL ESTATE GP LLC,**<br>its General Partner |
|  | &nbsp;&nbsp;**By:** | &nbsp;&nbsp;**CHIRON REAL ESTATE Inc.,**<br>its Sole Member |
|  | &nbsp;&nbsp;By: | &nbsp;&nbsp;<u>/s/ Robert Kiernan</u>  |
|  | &nbsp;&nbsp;Name: | &nbsp;&nbsp;Robert Kiernan |
|  | &nbsp;&nbsp;Title: | &nbsp;&nbsp;Treasurer and Chief Financial Officer |

---

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**JPMORGAN CHASE BANK, N.A.**, as Administrative Agent and Lender

By:<u>/s/ Jason Baeten</u> 

Name:Jason Baeten

Title:Executive Director

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**BANK OF MONTREAL, CHICAGO BRANCH**

By:<u>/s/ Darin Mainquist</u> 

Name:Darin Mainquist

Title:Managing Director

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**WELLS FARGO BANK, NATIONAL ASSOCIATION**

By:<u>/s/ Darin Mullis</u> 

Name:Darin Mullis

Title:Managing Director

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**CITIZENS BANK, N.A.**

By:<u>/s/ Lloyd Baron</u> 

Name:Lloyd Baron

Title:Senior Vice President

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**TRUIST BANK**

By:<u>/s/ Tim Conway</u> 

Name:Tim Conway

Title:Vice President

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**HUNTINGTON NATIONAL BANK**

By:<u>/s/ Michael Kinnick</u> 

Name:Michael Kinnick

Title:Managing Director

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**ASSOCIATED BANK, NATIONAL ASSOCIATION**

By:<u>/s/ Mitchell Vega</u> 

Name:Mitchell Vega

Title:Senior Vice President

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**RAYMOND JAMES BANK**

By:<u>/s/ Alexander Sierra</u> 

Name:Alexander Sierra

Title: Senior Vice President

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

**STIFEL BANK & TRUST**

By:<u>/s/ Matthew L. Diehl</u> 

Name:Matthew L. Diehl

Title:Senior Vice President

[Signature page to GMRE Amendment No. 1 to Third Amended and Restated Credit Agreement]

------

<u>Exhibit A</u>

<u>Conformed Version, including Amendment No. 1</u>

Execution Version

Third Amended and Restated Credit Agreement

Dated as of October 8, 2025

among

Global Medical Reit L.P.Chiron Real Estate LP, as<br> Borrower

The Guarantors from time to time party hereto,

the Lenders from time to time party hereto,

and

JPMorgan Chase Bank, N.A.,<br>as Administrative Agent

BMO Capital Markets Corp. and Wells Fargo Bank, N.A.,<br>as Syndication Agents

Citizens Bank, N.A., Huntington National Bank and Truist Bank,<br>as Documentation Agents

------

JPMorgan Chase Bank, N.A., BMO Capital Markets Corp.,<br>Wells Fargo Securities, LLC, Citizens Bank, N.A.,<br>Huntington National Bank and Truist Securities, Inc.,<br>as Joint Lead Arrangers and Joint Book Runners

------

**Table of Contents**

**Page**

<sup>SECTION 1. The Credit Facilities.</sup>[1](#_Toc206503133)

<sup>Section 1.1 Commitments.</sup>[1](#_Toc206503134)

<sup>Section 1.2 [Reserved].</sup>[2](#_Toc206503135)

<sup>Section 1.3 Letters of Credit.</sup>[2](#_Toc206503136)

<sup>Section 1.4 Applicable Interest Rates.</sup>[8](#_Toc206503137)

[Section 1.5](#_Toc206503138) [Minimum Borrowing Amounts; Maximum Term Benchmark Loans](#_Toc206503138)[8](#_Toc206503138)

[Section 1.6](#_Toc206503139) [Manner of Borrowing Loans and Designating Applicable Interest Rates.](#_Toc206503139)[9](#_Toc206503139)

<sup>Section 1.7 Maturity of Loans</sup>[11](#_Toc206503140)

<sup>Section 1.8 Prepayments.</sup>[11](#_Toc206503141)

<sup>Section 1.9 Default Rate</sup>[11](#_Toc206503142)

<sup>Section 1.10 Evidence of Indebtedness.</sup>[12](#_Toc206503143)

<sup>Section 1.11 Funding Indemnity</sup>[13](#_Toc206503144)

<sup>Section 1.12 Commitment Terminations.</sup>[13](#_Toc206503145)

<sup>Section 1.13 Substitution of Lenders</sup>[14](#_Toc206503146)

<sup>Section 1.14 Defaulting Lenders.</sup>[14](#_Toc206503147)

<sup>Section 1.15 Incremental Facilities.</sup>[17](#_Toc206503148)

[Section 1.16](#_Toc206503149) [Extension of Scheduled Termination Date](#_Toc206503149)[19](#_Toc206503149)

<sup>SECTION 2. Fees.</sup>[20](#_Toc206503151)

<sup>Section 2.1 Fees.</sup>[20](#_Toc206503152)

<sup>SECTION 3. Place and Application of Payments.</sup>[22](#_Toc206503153)

<sup>Section 3.1 Place and Application of Payments</sup>[22](#_Toc206503154)

<sup>Section 3.2 Account Debit</sup>[23](#_Toc206503155)

<sup>SECTION 4. Guaranties.</sup>[23](#_Toc206503156)

<sup>Section 4.1 Guaranties</sup>[23](#_Toc206503157)

<sup>Section 4.2 Further Assurances</sup>[24](#_Toc206503158)

<sup>SECTION 5. Definitions; Interpretation.</sup>[24](#_Toc206503159)

<sup>Section 5.1 Definitions</sup>[24](#_Toc206503160)

<sup>Section 5.2 Interpretation</sup>[65](#_Toc206503161)

<sup>Section 5.3 Change in Accounting Principles</sup>[65](#_Toc206503162)

&nbsp;&nbsp;-i-<br>

------

**Table of Contents**

(continued)

**Page**

[Section 5.4](#_Toc206503163) [Interest Rates; Benchmark Notification](#_Toc206503163)[66](#_Toc206503163)

<sup>Section 5.5 Letter of Credit Amounts</sup>[66](#_Toc206503164)

<sup>Section 5.6 Divisions</sup>[66](#_Toc206503165)

<sup>SECTION 6. Representations and Warranties.</sup>[66](#_Toc206503166)

<sup>Section 6.1 Organization and Qualification</sup>[67](#_Toc206503167)

<sup>Section 6.2 Subsidiaries</sup>[67](#_Toc206503168)

<sup>Section 6.3 Authority and Validity of Obligations</sup>[67](#_Toc206503169)

<sup>Section 6.4 Use of Proceeds; Margin Stock</sup>[68](#_Toc206503170)

<sup>Section 6.5 Financial Reports</sup>[68](#_Toc206503171)

<sup>Section 6.6 No Material Adverse Change</sup>[68](#_Toc206503172)

<sup>Section 6.7 Full Disclosure</sup>[69](#_Toc206503173)

<sup>Section 6.8 Trademarks, Franchises, and Licenses</sup>[69](#_Toc206503174)

<sup>Section 6.9 Governmental Authority and Licensing</sup>[69](#_Toc206503175)

<sup>Section 6.10 Good Title</sup>[69](#_Toc206503176)

<sup>Section 6.11 Litigation and Other Controversies</sup>[69](#_Toc206503177)

<sup>Section 6.12 Taxes</sup>[69](#_Toc206503178)

<sup>Section 6.13 Approvals</sup>[70](#_Toc206503179)

<sup>Section 6.14 [Reserved].</sup>[70](#_Toc206503180)

<sup>Section 6.15 Investment Company</sup>[70](#_Toc206503181)

<sup>Section 6.16 ERISA</sup>[70](#_Toc206503182)

<sup>Section 6.17 Compliance with Laws</sup>[70](#_Toc206503183)

<sup>Section 6.18 Anti-Corruption Laws and Sanctions</sup>[71](#_Toc206503184)

<sup>Section 6.19 Other Agreements</sup>[72](#_Toc206503185)

<sup>Section 6.20 Solvency</sup>[72](#_Toc206503186)

<sup>Section 6.21 No Default</sup>[72](#_Toc206503187)

<sup>Section 6.22 [Reserved].</sup>[72](#_Toc206503188)

[Section 6.23](#_Toc206503189) [Condition of Property; Casualties; Condemnation](#_Toc206503189)[72](#_Toc206503189)

<sup>Section 6.24 Legal Requirements and Zoning</sup>[72](#_Toc206503190)

<sup>Section 6.25 REIT Status</sup>[72](#_Toc206503191)

<sup>SECTION 7. Conditions Precedent.</sup>[73](#_Toc206503192)

&nbsp;&nbsp;-ii-<br>

------

**Table of Contents**

(continued)

**Page**

<sup>Section 7.1 All Credit Events</sup>[73](#_Toc206503193)

<sup>Section 7.2 Initial Credit Event</sup>[73](#_Toc206503194)

<sup>SECTION 8. Covenants.</sup>[75](#_Toc206503195)

<sup>Section 8.1 Maintenance of Existence</sup>[75](#_Toc206503196)

<sup>Section 8.2 Maintenance of Properties</sup>[76](#_Toc206503197)

<sup>Section 8.3 Taxes and Assessments</sup>[76](#_Toc206503198)

<sup>Section 8.4 Insurance</sup>[76](#_Toc206503199)

<sup>Section 8.5 Financial Reports</sup>[76](#_Toc206503200)

<sup>Section 8.6 Inspection</sup>[78](#_Toc206503201)

<sup>Section 8.7 Liens</sup>[79](#_Toc206503202)

[Section 8.8](#_Toc206503203) [Investments, Acquisitions, Loans and Advances](#_Toc206503203)[79](#_Toc206503203)

<sup>Section 8.9 Mergers, Consolidations and Sales</sup>[80](#_Toc206503204)

<sup>Section 8.10 [Reserved].</sup>[81](#_Toc206503205)

<sup>Section 8.11 ERISA</sup>[81](#_Toc206503206)

<sup>Section 8.12 Compliance with Laws</sup>[82](#_Toc206503207)

[Section 8.13](#_Toc206503208) [Compliance with Sanctions and Anti Corruption Laws](#_Toc206503208)[83](#_Toc206503208)

<sup>Section 8.14 Burdensome Contracts With Affiliates</sup>[83](#_Toc206503209)

<sup>Section 8.15 No Changes in Fiscal Year</sup>[83](#_Toc206503210)

<sup>Section 8.16 Formation of Subsidiaries</sup>[83](#_Toc206503211)

<sup>Section 8.17 Change in the Nature of Business</sup>[84](#_Toc206503212)

<sup>Section 8.18 Use of Proceeds</sup>[84](#_Toc206503213)

<sup>Section 8.19 [Reserved].</sup>[84](#_Toc206503214)

<sup>Section 8.20 Financial Covenants.</sup>[84](#_Toc206503215)

<sup>Section 8.21 Hedging Agreements</sup>[85](#_Toc206503216)

[Section 8.22](#_Toc206503217) [Electronic Delivery of Certain Information](#_Toc206503217)[85](#_Toc206503217)

<sup>Section 8.23 REIT Status</sup>[86](#_Toc206503218)

<sup>Section 8.24 Restricted Payments</sup>[86](#_Toc206503219)

<sup>Section 8.25 Management Fees</sup>[87](#_Toc206503220)

<sup>SECTION 9. Events of Default and Remedies.</sup>[87](#_Toc206503221)

<sup>Section 9.1 Events of Default</sup>[87](#_Toc206503222)

&nbsp;&nbsp;-iii-<br>

------

**Table of Contents**

(continued)

**Page**

<sup>Section 9.2 Non-Bankruptcy Defaults</sup>[90](#_Toc206503223)

<sup>Section 9.3 Bankruptcy Defaults</sup>[90](#_Toc206503224)

[Section 9.4](#_Toc206503225) [Collateral for Undrawn Letters of Credit](#_Toc206503225)[90](#_Toc206503225)

<sup>SECTION 10. Change in Circumstances.</sup>[92](#_Toc206503226)

<sup>Section 10.1 Change of Law</sup>[92](#_Toc206503227)

<sup>Section 10.2 Alternate Rate of Interest</sup>[92](#_Toc206503228)

<sup>Section 10.3 Increased Cost and Reduced Return</sup>[93](#_Toc206503229)

<sup>Section 10.4 Lending Offices</sup>[95](#_Toc206503230)

<sup>Section 10.5 [Reserved].</sup>[95](#_Toc206503231)

<sup>Section 10.6 Benchmark Transition.</sup>[95](#_Toc206503232)

<sup>SECTION 11. The Administrative Agent.</sup>[96](#_Toc206503233)

<sup>Section 11.1 Appointment and Authority</sup>[96](#_Toc206503234)

<sup>Section 11.2 Rights as a Lender</sup>[97](#_Toc206503235)

[Section 11.3](#_Toc206503236) [Action by Administrative Agent; Exculpatory Provisions](#_Toc206503236)[97](#_Toc206503236)

<sup>Section 11.4 Reliance by Administrative Agent</sup>[99](#_Toc206503237)

<sup>Section 11.5 Delegation of Duties</sup>[99](#_Toc206503238)

[Section 11.6](#_Toc206503239) [Resignation of Administrative Agent; Removal of Administrative Agent](#_Toc206503239)[100](#_Toc206503239)

[Section 11.7](#_Toc206503240) [Non-Reliance on Administrative Agent and Other Lenders](#_Toc206503240)[100](#_Toc206503240)

<sup>Section 11.8 L/C Issuer</sup>[102](#_Toc206503241)

[Section 11.9](#_Toc206503242) [Hedging Liability and Bank Product Obligations](#_Toc206503242)[102](#_Toc206503242)

<sup>Section 11.10 Designation of Additional Agents</sup>[103](#_Toc206503243)

<sup>Section 11.11 Erroneous Payments.</sup>[103](#_Toc206503244)

<sup>Section 11.12 Authorization to Release Guaranties</sup>[104](#_Toc206503245)

[Section 11.13](#_Toc206503246) [Authorization of Administrative Agent to File Proofs of Claim](#_Toc206503246)[104](#_Toc206503246)

<sup>Section 11.14 Certain ERISA Matters</sup>[105](#_Toc206503247)

<sup>SECTION 12. Miscellaneous.</sup>[108](#_Toc206503248)

<sup>Section 12.1 Taxes</sup>[108](#_Toc206503249)

<sup>Section 12.2 [Reserved]</sup>

<sup>Section 12.3 No Waiver, Cumulative Remedies</sup>[112](#_Toc206503251)

&nbsp;&nbsp;-iv-<br>

------

**Table of Contents**

(continued)

**Page**

<sup>Section 12.4 Non-Business Days</sup>[112](#_Toc206503252)

<sup>Section 12.5 Survival of Representations</sup>[113](#_Toc206503253)

<sup>Section 12.6 Survival of Indemnities</sup>[113](#_Toc206503254)

<sup>Section 12.7 Sharing of Set-Off</sup>[113](#_Toc206503255)

<sup>Section 12.8 Notices</sup>[113](#_Toc206503256)

[Section 12.9](#_Toc206503257) [Counterparts; Integration; Effectiveness.](#_Toc206503257)[116](#_Toc206503257)

<sup>Section 12.10 Successors and Assigns</sup>[118](#_Toc206503258)

<sup>Section 12.11 Participants</sup>[118](#_Toc206503259)

<sup>Section 12.12 Assignments</sup>[119](#_Toc206503260)

<sup>Section 12.13 Amendments</sup>[122](#_Toc206503261)

<sup>Section 12.14 Headings</sup>[124](#_Toc206503262)

<sup>Section 12.15 Costs and Expenses; Indemnification</sup>[124](#_Toc206503263)

<sup>Section 12.16 Set-off</sup>[127](#_Toc206503264)

<sup>Section 12.17 Entire Agreement</sup>[127](#_Toc206503265)

<sup>Section 12.18 Waiver of Jury Trial</sup>[127](#_Toc206503266)

<sup>Section 12.19 Severability of Provisions</sup>[127](#_Toc206503267)

<sup>Section 12.20 Excess Interest</sup>[128](#_Toc206503268)

<sup>Section 12.21 Construction</sup>[128](#_Toc206503269)

[Section 12.22](#_Toc206503270) [Lender's and L/C Issuer's Obligations Several](#_Toc206503270)[128](#_Toc206503270)

[Section 12.23](#_Toc206503271) [Governing Law; Jurisdiction; Consent to Service of Process](#_Toc206503271)[128](#_Toc206503271)

<sup>Section 12.24 USA Patriot Act</sup>[129](#_Toc206503272)

<sup>Section 12.25 Confidentiality</sup>[129](#_Toc206503273)

[Section 12.26](#_Toc206503274) [Acknowledgement and Consent to Bail-In of Affected Financial Institutions](#_Toc206503274)[130](#_Toc206503274)

[Section 12.27](#_Toc206503275) [Acknowledgement Regarding Any Supported QFCs](#_Toc206503275)[131](#_Toc206503275)

<sup>Section 12.28 No Fiduciary Duty</sup>[132](#_Toc206503276)

<sup>Section 12.29 Transitional Arrangements.</sup>[132](#_Toc206503277)

<sup>SECTION 13. The Guarantees.</sup>[134](#_Toc206503278)

<sup>Section 13.1 The Guarantees</sup>[134](#_Toc206503279)

<sup>Section 13.2 Guarantee Unconditional</sup>[134](#_Toc206503280)

&nbsp;&nbsp;-v-<br>

------

**Table of Contents**

(continued)

**Page**

[Section 13.3](#_Toc206503281) [Discharge upon Payment in Full or Investment Grade Rating; Reinstatement in Certain Circumstances](#_Toc206503281)[135](#_Toc206503281)

<sup>Section 13.4 Subrogation</sup>[136](#_Toc206503282)

<sup>Section 13.5 Waivers</sup>[136](#_Toc206503283)

<sup>Section 13.6 Limit on Recovery</sup>[136](#_Toc206503284)

<sup>Section 13.7 Stay of Acceleration</sup>[136](#_Toc206503285)

<sup>Section 13.8 Benefit to Guarantors</sup>[137](#_Toc206503286)

<sup>Section 13.9 Guarantor Covenants</sup>[137](#_Toc206503287)

<sup>Section 13.10 Subordination</sup>[137](#_Toc206503288)

<sup>Section 13.11 Keepwell</sup>[137](#_Toc206503289)

&nbsp;&nbsp;-vi-<br>

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Exhibit A | &nbsp;&nbsp;— | &nbsp;&nbsp;Notice of Payment Request |
| &nbsp;&nbsp;Exhibit B | &nbsp;&nbsp;— | &nbsp;&nbsp;[Reserved] |
| &nbsp;&nbsp;Exhibit C | &nbsp;&nbsp;— | &nbsp;&nbsp;[Reserved] |
| &nbsp;&nbsp;Exhibit D-1 | &nbsp;&nbsp;— | &nbsp;&nbsp;Revolving Note |
| &nbsp;&nbsp;Exhibit D-2 | &nbsp;&nbsp;— | &nbsp;&nbsp;Tranche A Term Note |
| &nbsp;&nbsp;Exhibit D-3 | &nbsp;&nbsp;— | &nbsp;&nbsp;Tranche B Term Note |
| &nbsp;&nbsp;Exhibit D-4 | &nbsp;&nbsp;— | &nbsp;&nbsp;Incremental Term Note |
| &nbsp;&nbsp;Exhibit E | &nbsp;&nbsp;— | &nbsp;&nbsp;Compliance Certificate |
| &nbsp;&nbsp;Exhibit F | &nbsp;&nbsp;— | &nbsp;&nbsp;Assignment and Acceptance |
| &nbsp;&nbsp;Exhibit G | &nbsp;&nbsp;— | &nbsp;&nbsp;Additional Guarantor Supplement |
| &nbsp;&nbsp;Exhibit H | &nbsp;&nbsp;— | &nbsp;&nbsp;Commitment Amount Increase Request |
| &nbsp;&nbsp;Exhibit I | &nbsp;&nbsp;— | &nbsp;&nbsp;[Reserved] |
| &nbsp;&nbsp;Exhibit J-1 | &nbsp;&nbsp;— | &nbsp;&nbsp;Form of U.S. Tax Compliance Certificate |
| &nbsp;&nbsp;Exhibit J-2 | &nbsp;&nbsp;— | &nbsp;&nbsp;Form of U.S. Tax Compliance Certificate |
| &nbsp;&nbsp;Exhibit J-3 | &nbsp;&nbsp;— | &nbsp;&nbsp;Form of U.S. Tax Compliance Certificate |
| &nbsp;&nbsp;Exhibit J-4 | &nbsp;&nbsp;— | &nbsp;&nbsp;Form of U.S. Tax Compliance Certificate |
| &nbsp;&nbsp;Schedule 1 | &nbsp;&nbsp;— | &nbsp;&nbsp;Commitments |
| &nbsp;&nbsp;Schedule 1B | &nbsp;&nbsp;— | &nbsp;&nbsp;L/C Commitments |
| &nbsp;&nbsp;Schedule 1.1 | &nbsp;&nbsp;— | &nbsp;&nbsp;Initial Unencumbered Properties |
| &nbsp;&nbsp;Schedule 1.2 | &nbsp;&nbsp;— | &nbsp;&nbsp;Existing Liens |
| &nbsp;&nbsp;Schedule 1.3 | &nbsp;&nbsp;--- | &nbsp;&nbsp;Existing Letters of Credit |
| &nbsp;&nbsp;Schedule 1.4 | &nbsp;&nbsp;— | &nbsp;&nbsp;Qualified Ground Leases |
| &nbsp;&nbsp;Schedule 6.2 | &nbsp;&nbsp;— | &nbsp;&nbsp;Subsidiaries |
| &nbsp;&nbsp;Schedule 6.11<br>Schedule 6.17 | &nbsp;&nbsp;—<br>— | &nbsp;&nbsp;Litigation<br>Environmental |
| &nbsp;&nbsp;Schedule 8.8 | &nbsp;&nbsp;— | &nbsp;&nbsp;Investments |

---

-vii-

------

#### Third Amended and Restated Credit Agreement
This Third Amended and Restated Credit Agreement (this "*Agreement*") is entered into as of October <u>8</u>__, 2025 by and among CHIRON REAL ESTATE LP (f/k/a Global MedicalGLOBAL MEDICAL REIT L.P.), a Delaware limited partnership (the "*Borrower*"), <u>CHIRON REAL ESTATE INC. (f/k/a Global</u> MedicalGLOBAL MEDICAL REIT <u>Inc.),</u>INC., a Maryland corporation (the "*Parent*" or "*Chiron*"*Global Medical REIT*"), the certain Subsidiaries from time to time party to this Agreement as Guarantors, the several financial institutions from time to time party to this Agreement, as Lenders, and JPMorgan Chase Bank, N.A., as Administrative Agent as provided herein. All capitalized terms used herein without definition shall have the same meanings herein as such terms are defined in Section 5.1 hereof.

#### Preliminary Statement
Whereas, the Borrower, the Parent, JPMorgan Chase Bank, N.A., as administrative agent, and certain lenders and guarantors are parties to a Second Amended and Restated Credit Agreement dated as of May 3, 2021, as amended to date (the "*Existing Credit Agreement*"), pursuant to which such lenders agreed to provide credit facilities to the Borrower;

Whereas, the Borrower, the Parent, the Administrative Agent and the Lenders wish to amend and restate the Existing Credit Agreement in its entirety as set forth herein;

Whereas, it is the intent of the parties that this Agreement shall not constitute a novation of the obligations and liabilities of the parties under the Existing Credit Agreement and that this Agreement amends and restates in its entirety the Existing Credit Agreement;

Whereas, the Borrower has requested that the Lenders provide revolving credit and term loan facilities to the Borrower, and the Administrative Agent, the L/C Issuer and the Lenders have agreed to provide such credit facilities on the terms and conditions set forth in this Agreement.

Now, Therefore, in consideration of the mutual agreements contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby amend and restate the Existing Credit Agreement in its entirety and covenant and agree as follows:

Section 1. The Credit Facilities.

*Section 1.1. Commitments*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*Revolving Credit Commitments*. Subject to the terms and conditions hereof, each Lender, by its acceptance hereof, severally agrees to make a loan or loans (individually a "*Revolving Loan*" and collectively for all the Lenders the "*Revolving Loans*") in U.S. Dollars to the Borrower from time to time during the Availability Period on a revolving basis up to the amount of such Lender's Revolving Credit Commitment, subject to any reductions thereof pursuant to the terms hereof, before the Termination Date. The sum of the aggregate principal amount of Revolving Loans and L/C Obligations at any time outstanding shall not exceed the Revolving Credit Commitments of all Lenders in effect at such time. Each Borrowing of Revolving Loans shall be made ratably by the Lenders in proportion to their respective Revolver Percentages.

------

As provided in Section 1.6(a) hereof, the Borrower may elect that each Borrowing of Revolving Loans be either Base Rate Loans, Term Benchmark Loans or RFR Loans. Revolving Loans may be repaid and the principal amount thereof reborrowed before the Termination Date, subject to the terms and conditions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Tranche A Term Loan Commitments*. The Lenders with Tranche A Term Loan Commitments under the Existing Credit Agreement made term loans in U.S. Dollars to the Borrower in the aggregate principal amount of $350,000,000 (which were designated as "*Tranche A Term Loans*"). Subject to the terms and conditions of this Agreement, on the Closing Date, such term loans shall continue to be outstanding under this Agreement and shall be divided into tranches and redesignated hereunder as "*Tranche A-1 Term Loans*" (the "*Tranche A-1 Term Loans*"), "*Tranche A-2 Term Loans*" (the "*Tranche A-2 Term Loans*") and "*Tranche A-3 Term Loans*" (the "*Tranche A-3 Term Loans*"). On the Closing Date, the Tranche A-1 Term Loans shall be in the aggregate principal amount of $100,000,000 and be reallocated to the Tranche A-1 Lenders in accordance with their Tranche A-1 Term Loan Commitments as set forth on Schedule 1 attached hereto in accordance with Section 12.29(a) hereof. On the Closing Date, the Tranche A-2 Term Loans shall be in the aggregate principal amount of $100,000,000 and shall be reallocated to the Tranche A-2 Lenders in accordance with their Tranche A-2 Term Loan Commitments as set forth on Schedule 1 attached hereto in accordance with Section 12.29(a) hereof. On the Closing Date, the Tranche A-3 Term Loans shall be in the aggregate principal amount of $150,000,000 and shall be reallocated to the Tranche A-3 Lenders in accordance with their Tranche A-3 Term Loan Commitments as set forth on Schedule 1 in accordance with Section 12.29(a) hereof. As provided in Section 1.6(a) hereof, the Borrower may elect that any Tranche A Term Loans be outstanding as Base Rate Loans, RFR Loans or Term Benchmark Loans. No amount repaid or prepaid on any Tranche A Term Loan may be borrowed again.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*Tranche B Term Loan Commitments*. The Lenders with Tranche B Term Loan Commitments under the Existing Credit Agreement made term loans in U.S. Dollars to the Borrower in the aggregate principal amount of $150,000,000 (which were designated as "*Tranche B Term Loans*"). Subject to the terms and conditions of this Agreement, on the Closing Date, such term loans shall continue to be outstanding under this Agreement as Tranche B Term Loans and shall continue to be held by the Tranche B Lenders in accordance with their Tranche B Term Loan Commitments as set forth on Schedule 1. As provided in Section 1.6(a) hereof, the Borrower may elect that the Tranche B Term Loans be outstanding as Base Rate Loans, RFR Loans or Term Benchmark Loans. No amount repaid or prepaid on any Tranche B Term Loan may be borrowed again.

*Section 1.2.*[*Reserved*].

*Section 1.3. Letters of Credit*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)*General Terms*. Subject to the terms and conditions hereof, as part of the Revolving Credit, the L/C Issuer shall issue standby letters of credit (each a "*Letter of Credit*") or amend or extend Letters of Credit issued by it for the account of the Borrower or for the account of the Borrower and one or more of its Subsidiaries in an aggregate undrawn face amount up to the L/C Sublimit; <u>provided</u> no L/C Issuer shall be under any obligation to issue a Letter of Credit that would result in more than a total of 20 Letters of Credit outstanding. A Letter of Credit shall be

------

issued, amended or extended only if (and upon issuance, amendment or extension of each Letter of Credit the Borrower shall be deemed to represent and warrant that), after giving effect to such issuance, amendment or extension (i) (x) the aggregate undrawn amount of all outstanding Letters of Credit issued by any L/C Issuer at such time plus (y) the aggregate amount of all unpaid Reimbursement Obligations owing to such L/C Issuer at such time shall not exceed its L/C Commitment, (ii) the L/C Obligations shall not exceed the total L/C Commitments, (iii) no Lender's Revolving Loans and L/C Obligations shall exceed its Revolving Commitment and (iv) the sum of the total Revolving Loans and L/C Obligations shall not exceed the total Revolving Commitments. The Borrower may, at any time and from time to time, reduce the L/C Commitment of any L/C Issuer with the consent of such L/C Issuer; <u>provided</u> that the Borrower shall not reduce the L/C Commitment of any L/C Issuer if, after giving effect to such reduction, the conditions set forth in clauses (i) through (iv) above shall not be satisfied. Each Letter of Credit shall be issued by the L/C Issuer, but each Lender shall be obligated to reimburse the L/C Issuer for such Lender's Revolver Percentage of the amount of each drawing thereunder and, accordingly, each Letter of Credit shall constitute usage of the Revolving Credit Commitment of each Lender pro rata in an amount equal to its Revolver Percentage of the L/C Obligations then outstanding.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)*Applications*. At any time prior to thirty (30) days before the Termination Date, the L/C Issuer shall, at the request of the Borrower, issue one or more Letters of Credit in U.S. Dollars, in a form reasonably satisfactory to the L/C Issuer, with expiration dates no later than the earlier of twelve (12) months from the date of issuance (or which are cancellable not later than twelve (12) months from the date of issuance and each renewal) or five (5) Business Days prior to the Termination Date (subject to the sentence below in respect of Letters of Credit with expiration dates that are automatically extended), in an aggregate face amount up to the L/C Sublimit, upon the receipt of an application duly executed by the Borrower and, if such Letter of Credit is for the account of one of its Subsidiaries, such Subsidiary for the relevant Letter of Credit in the form then customarily prescribed by the L/C Issuer for the Letter of Credit requested and in a form reasonably acceptable to the L/C Issuer (each an "*Application*"); *provided*, *however*, that the L/C Issuer may issue Letters of Credit with expiration dates later than the date that is five (5) Business Days prior to the Termination Date if the Borrower and the L/C Issuer enter into arrangements for the Cash Collateralization or backstop of such Letters of Credit in a manner reasonably satisfactory to the L/C Issuer. Notwithstanding anything contained in any Application to the contrary: (i) the Borrower shall pay fees in connection with each Letter of Credit as set forth in Section 2.1 hereof, (ii) except as otherwise provided in Section 1.8 or Section 1.14 hereof, unless an Event of Default is then continuing, the L/C Issuer will not call for the funding by the Borrower of any amount under a Letter of Credit before being presented with a drawing thereunder, and (iii) if the L/C Issuer is not timely reimbursed for the amount of any drawing under a Letter of Credit on the date such drawing is paid, unless a Loan shall be made on such date in the amount of the Reimbursement Obligations and the proceeds thereof applied to pay such Reimbursement Obligations as contemplated by the last sentence of Section 1.3(c) hereof, the Reimbursement Obligations for the amount of such drawing shall bear interest (which the Borrower hereby promises to pay) from and after the date such drawing is paid at a rate per annum equal to the sum of the Applicable Margin plus the Base Rate from time to time in effect (computed on the basis of a year of 365 or 366 days, as the case may be, and the actual number of days elapsed). If the L/C Issuer issues any Letter of Credit with an expiration date that is automatically extended unless the L/C Issuer gives notice that the expiration date will not so extend beyond its then scheduled expiration date, then the L/C Issuer will, unless the Administrative Agent and the Required

------

Lenders instruct the L/C Issuer otherwise, give such notice of non-renewal before the time necessary to prevent such automatic extension if before such required notice date: (i) the expiration date of such Letter of Credit if so extended would be after the date that is five (5) Business Days prior to the Termination Date unless such Letter of Credit is addressed in accordance with the provisions of the proviso of the final sentence of this Section 1.3(b), (ii) the Revolving Credit Commitments have been terminated, or (iii) a Default or an Event of Default is then continuing and the Required Lenders (or the Administrative Agent at their direction) have given the L/C Issuer instructions not to so permit the extension of the expiration date of such Letter of Credit. The L/C Issuer agrees to issue amendments to the Letter(s) of Credit increasing the amount, or extending the expiration date, thereof at the request of the Borrower subject to the conditions of Section 7 hereof and the other terms of this Section 1.3. Notwithstanding anything contained herein to the contrary, the L/C Issuer shall be under no obligation to issue, extend or amend any Letter of Credit if a default of any Lender's obligations to fund under Section 1.3(c) exists or any Lender is at such time a Defaulting Lender hereunder, unless the L/C Issuer has entered into arrangements with Borrower or such Lender satisfactory to the L/C Issuer to eliminate the L/C Issuer's risk with respect to such Lender.

In addition, an L/C Issuer shall not be under any obligation to issue, amend or extend any Letter of Credit if:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain such L/C Issuer from issuing, amending or extending such Letter of Credit, or request that such L/C Issuer refrain from issuing, amending or extending such Letter of Credit, or any law applicable to such L/C Issuer shall prohibit, or require that such L/C Issuer refrain from, the issuance, amendment or extension of letters of credit generally or such Letter of Credit in particular or shall impose upon such L/C Issuer with respect to such Letter of Credit any restriction, reserve or capital requirement (for which such L/C Issuer is not otherwise compensated hereunder) not in effect on the Closing Date, or shall impose upon such L/C Issuer any unreimbursed loss, cost or expense that was not applicable on the Closing Date and that such L/C Issuer in good faith deems material to it; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)the issuance, amendment or extension of such Letter of Credit would violate one or more policies of such L/C Issuer applicable to letters of credit generally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)*The Reimbursement Obligations*. Upon receipt from the beneficiary of any Letter of Credit of any notice of a drawing under such Letter of Credit, the L/C Issuer shall promptly notify the Borrower and the Administrative Agent thereof. Subject to Section 1.3(b) hereof, the obligation of the Borrower to reimburse the L/C Issuer for all drawings under a Letter of Credit (a "*Reimbursement Obligation*") shall be governed by the Application related to such Letter of Credit, except that reimbursement shall be made by no later than 12:00 noon (New York City time) on the date when each drawing is to be paid if the Borrower has been informed of such drawing by the L/C Issuer on or before 10:00 a.m. (New York City time) on the date when such drawing is to be paid or, if notice of such drawing is given to the Borrower after 10:00 a.m. (New York City time) on the date when such drawing is to be paid, by no later than 12:00 noon (New York City time) on the following Business Day, in immediately available funds at the Administrative Agent's principal office in New York City or such other office as the Administrative Agent may designate

------

in writing to the Borrower, and the Administrative Agent; <u>provided</u> that the Borrower may, subject to the conditions to borrowing set forth herein, request in accordance with Section 1.6(a) that such payment be financed with a Borrowing of Revolving Loans that are Base Rate Loans in an equivalent amount and, to the extent so financed, the Borrower's obligation to make such payment shall be discharged and replaced by the resulting Revolving Loan. The Administrative Agent shall thereafter cause to be distributed to the L/C Issuer the amounts so received in like funds. If the Borrower does not make any such reimbursement payment on the date due and the Participating Lenders fund their participations therein in the manner set forth in Section 1.3(e) below, then all payments thereafter received by the Administrative Agent in discharge of any of the relevant Reimbursement Obligations shall be distributed in accordance with Section 1.3(e) below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)*Obligations Absolute*. The Borrower's obligation to reimburse L/C Obligations as provided in subsection (c) of this Section shall be absolute, unconditional and irrevocable, and shall be performed strictly in accordance with the terms of this Agreement and the relevant Application under any and all circumstances whatsoever and irrespective of (i) any lack of validity or enforceability of any Letter of Credit or this Agreement, or any term or provision therein, (ii) any draft or other document presented under a Letter of Credit proving to be forged, fraudulent or invalid in any respect or any statement therein being untrue or inaccurate in any respect, (iii) payment by the L/C Issuer under a Letter of Credit against presentation of a draft or other document that does not strictly comply with the terms of such Letter of Credit, or (iv) any other event or circumstance whatsoever, whether or not similar to any of the foregoing, that might, but for the provisions of this Section, constitute a legal or equitable discharge of, or provide a right of setoff against, the Borrower's obligations hereunder, except, in each case, to the extent of any direct damages (as opposed to consequential damages, claims in respect of which are hereby waived by the Borrower to the extent permitted by applicable Legal Requirements) suffered by the Borrower that are caused by the L/C Issuer's gross negligence, bad faith or willful misconduct on the part of the L/C Issuer (as determined by a court of competent jurisdiction by final and non-appealable judgment). None of the Administrative Agent, the Lenders, or the L/C Issuer shall have any liability or responsibility by reason of or in connection with the issuance or transfer of any Letter of Credit or any payment or failure to make any payment thereunder (irrespective of any of the circumstances referred to in the preceding sentence), or any error, omission, interruption, loss or delay in transmission or delivery of any draft, notice or other communication under or relating to any Letter of Credit (including any document required to make a drawing thereunder), any error in interpretation of technical terms or any consequence arising from causes beyond the control of the L/C Issuer; provided that the foregoing shall not be construed to excuse the L/C Issuer from liability to the Borrower to the extent of any direct damages (as opposed to consequential damages, claims in respect of which are hereby waived by the Borrower to the extent permitted by applicable Legal Requirements) suffered by the Borrower that are caused by the L/C Issuer's failure to exercise care when determining whether drafts and other documents presented under a Letter of Credit comply with the terms thereof. The parties hereto expressly agree that, in the absence of gross negligence, bad faith or willful misconduct on the part of the L/C Issuer (as determined by a court of competent jurisdiction by final and non-appealable judgment), the L/C Issuer shall be deemed to have exercised care in each such determination. In furtherance of the foregoing and without limiting the generality thereof, the parties agree that, with respect to documents presented which appear on their face to be in substantial compliance with the terms of a Letter of Credit, the L/C Issuer may, in its sole discretion, either accept and make payment upon such documents without responsibility for further investigation, regardless of any notice or information to the

------

contrary, or refuse to accept and make payment upon such documents if such documents are not in strict compliance with the terms of such Letter of Credit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)*The Participating Interests*. Each Lender (other than the Lender acting as L/C Issuer in issuing the relevant Letter of Credit), by its acceptance hereof, severally agrees to purchase from the L/C Issuer, and the L/C Issuer hereby agrees to sell to each such Lender (a "*Participating Lender*"), an undivided percentage participating interest (a "*Participating Interest*"), to the extent of its Revolver Percentage, in each Letter of Credit issued by, and each Reimbursement Obligation owed to, the L/C Issuer. Upon any failure by the Borrower to pay any Reimbursement Obligation at the time required on the date the related drawing is to be paid, as set forth in Section 1.3(c) above, or if the L/C Issuer is required at any time to return to the Borrower or to a trustee, receiver, liquidator, custodian or other Person any portion of any payment of any Reimbursement Obligation, each Participating Lender shall, not later than the Business Day it receives a certificate in the form of Exhibit A hereto from the L/C Issuer (with a copy to the Administrative Agent) to such effect, if such certificate is received before 12:00 noon (New York City time), or not later than 12:00 noon (New York City time), on the following Business Day, if such certificate is received after such time, pay to the Administrative Agent for the account of the L/C Issuer an amount equal to such Participating Lender's Revolver Percentage of such unpaid or recaptured Reimbursement Obligation together with interest on such amount accrued from the date the related payment was made by the L/C Issuer to the date of such payment by such Participating Lender at a rate per annum equal to: (i) from the date the related payment was made by the L/C Issuer to the date two (2) Business Days after payment by such Participating Lender is due hereunder, the Federal Funds Effective Rate for each such day and (ii) from the date two (2) Business Days after the date such payment is due from such Participating Lender to the date such payment is made by such Participating Lender, the Base Rate in effect for each such day. Each such Participating Lender shall thereafter be entitled to receive its Revolver Percentage of each payment received in respect of the relevant Reimbursement Obligation and of interest paid thereon, with the L/C Issuer retaining its Revolver Percentage thereof as a Lender hereunder. The several obligations of the Participating Lenders to the L/C Issuer under this Section 1.3 shall be absolute, irrevocable, and unconditional under any and all circumstances whatsoever and shall not be subject to any set-off, counterclaim or defense to payment which any Participating Lender may have or have had against the Borrower, the L/C Issuer, the Administrative Agent, any Lender or any other Person whatsoever. Without limiting the generality of the foregoing, such obligations shall not be affected by any Default or Event of Default or by any reduction or termination of any Commitment of any Lender, and each payment by a Participating Lender under this Section 1.3 shall be made without any offset, abatement, withholding or reduction whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)*Indemnification*. The Participating Lenders shall, to the extent of their respective Revolver Percentages, indemnify the L/C Issuer (to the extent not reimbursed by the Borrower) against any cost, expense (including reasonable counsel fees and disbursements), claim, demand, action, loss or liability (except such as result from such L/C Issuer's gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and non-appealable judgment) that the L/C Issuer may suffer or incur in connection with any Letter of Credit issued by it. The obligations of the Participating Lenders under this Section 1.3(f) and all other parts of this Section 1.3 shall survive termination of this Agreement and of all Applications, Letters of Credit, and all drafts and other documents presented in connection with drawings thereunder.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)*Manner of Requesting a Letter of Credit*. The Borrower shall provide at least five (5) Business Days' advance written notice to the Administrative Agent of each request (which may be transmitted by electronic communication, including an Approved Borrower Portal, if arrangements for doing so have been approved by the respective L/C Issuer) for the issuance of a Letter of Credit, such notice in each case to be accompanied by an Application for such Letter of Credit properly completed and executed by the Borrower and, in the case of an extension or amendment or an increase in the amount of a Letter of Credit, a written request therefor , in a form reasonably acceptable to the Administrative Agent and the L/C Issuer, in each case, together with the fees called for by this Agreement. Such request shall specify the date of issuance, amendment or extension (which shall be a Business Day), the date on which such Letter of Credit is to expire (which shall comply with this Section), the amount of such Letter of Credit, the name and address of the beneficiary thereof and such other information as shall be necessary to prepare, amend or extend such Letter of Credit. In the event of any inconsistency between the terms and conditions of this Agreement and the terms and conditions of any Application, the terms and conditions of this Agreement shall control. The Administrative Agent shall promptly notify the L/C Issuer of the Administrative Agent's receipt of each such notice (and the L/C Issuer shall be entitled to assume that the conditions precedent to any such issuance, extension, amendment or increase have been satisfied unless notified to the contrary by the Administrative Agent or the Required Lenders) and the L/C Issuer shall promptly notify the Administrative Agent and the Lenders of the issuance of the Letter of Credit so requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)*Replacement of the L/C Issuer*. The L/C Issuer may be replaced at any time by any other Lender or an Affiliate of any Lender by written agreement among the Borrower, the Administrative Agent, the replaced L/C Issuer and the successor L/C Issuer. The Administrative Agent shall notify the Lenders of any such replacement of the L/C Issuer. At the time any such replacement shall become effective, the Borrower shall pay all unpaid fees accrued for the account of the replaced L/C Issuer. From and after the effective date of any such replacement (i) the successor L/C Issuer shall have all the rights and obligations of the L/C Issuer under this Agreement with respect to Letters of Credit to be issued thereafter and (ii) references herein to the term "*L/C Issuer*" shall be deemed to refer to such successor or to any previous L/C Issuer, or to such successor and all previous L/C Issuers, as the context shall require. After the replacement of a L/C Issuer hereunder, the replaced L/C Issuer shall remain a party hereto and shall continue to have all the rights and obligations of a L/C Issuer under this Agreement with respect to Letters of Credit issued by it prior to such replacement, but shall not be required to issue additional Letters of Credit.

Subject to the appointment and acceptance of a successor L/C Issuer, any L/C Issuer may resign as an L/C Issuer at any time upon thirty days' prior written notice to the Administrative Agent, the Borrower and the Lenders, in which case, such resigning L/C Issuer shall be replaced in accordance with the paragraph above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)*Letters of Credit Issued for Account of Subsidiaries*. Notwithstanding that a Letter of Credit issued or outstanding hereunder supports any obligations of, or is for the account of, a Subsidiary, or states that a Subsidiary is the "account party," "applicant," "customer," "instructing party," or the like of or for such Letter of Credit, and without derogating from any rights of the applicable L/C Issuer (whether arising by contract, at law, in equity or otherwise) against such Subsidiary in respect of such Letter of Credit, the Borrower (i) shall reimburse, indemnify and

------

compensate the applicable L/C Issuer hereunder for such Letter of Credit (including to reimburse any and all drawings thereunder) as if such Letter of Credit had been issued solely for the account of the Borrower and (ii) irrevocably waives any and all defenses (other than actual payment and performance) that might otherwise be available to it as a guarantor or surety of any or all of the obligations of such Subsidiary in respect of such Letter of Credit. The Borrower hereby acknowledges that the issuance of such Letters of Credit for its Subsidiaries inures to the benefit of the Borrower, and that the Borrower's business derives substantial benefits from the businesses of such Subsidiaries.

*Section 1.4. Applicable Interest Rates*.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)*Rate Determinations*. The Administrative Agent shall determine each interest rate applicable to the Loans and the Reimbursement Obligations hereunder and shall promptly, upon each such determination, notify the Borrower thereof, and its good faith determination thereof shall be conclusive and binding except in the case of manifest error.

*Section 1.5. Minimum Borrowing Amounts; Maximum Term Benchmark Loans*. Each Borrowing of Base Rate Loans or RFR Loans advanced under a Credit shall be in an amount not less than $100,000 or such greater amount which is an integral multiple of $100,000. Each Borrowing of Term Benchmark Loans advanced, continued or converted to under a Credit shall be in an amount equal to $500,000 or such greater amount which is an integral multiple of

------

$100,000. Without the Administrative Agent's consent, there shall not be more than nine (9) Borrowings of Term Benchmark Loans outstanding hereunder.

*Section 1.6. Manner of Borrowing Loans and Designating Applicable Interest Rates*.

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATIONS**

I, Mark O. Decker, Jr., certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2026 of Chiron Real Estate Inc. (the "registrant") **;** 

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 7, 2026 | */s/ Mark O. Decker, Jr.* |
|  | Mark O. Decker, Jr., Chief Executive Officer |
|  | (Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATIONS**

I, Robert J. Kiernan, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2026 of Chiron Real Estate Inc. (the "registrant") **;** 

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | |
|:---|:---|
| Date: May 7, 2026 | */s/ Robert J. Kiernan* |
|  | Robert J. Kiernan, Chief Financial Officer |
|  | (Principal Financial and Accounting Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**Section 1350 Certification of Chief Executive Officer and Chief Financial Officer**

In connection with the Quarterly Report on Form 10-Q of Chiron Real Estate Inc. (the "Company") for the period ended March 31, 2026 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Mark O. Decker, Jr., Chief Executive Officer of the Company and I, Robert J. Kiernan, Chief Financial Officer of the Company, each certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | |
|:---|:---|
| Date: May 7, 2026 | */s/ Mark O. Decker, Jr.* |
|  | Mark O. Decker, Jr., Chief Executive Officer |
|  | (Principal Executive Officer) |

---

---

| | |
|:---|:---|
| Date: May 7, 2026 | */s/ Robert J. Kiernan* |
|  | Robert J. Kiernan, Chief Financial Officer |
|  | (Principal Financial and Accounting Officer) |

---

*This certification accompanies this Quarterly Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.*

------